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 ABSTRACT  
Pranita Katwa. MAST CELLS AND THE IL-33/ST2 AXIS ARE ESSENTIAL 
DETERMINANTS OF CARBON NANOTUBE TOXICITY (under the direction of Jared 
M. Brown, Ph.D.) Department of Pharmacology and Toxicology, June 28, 2012. 
 
The rise of nanomaterial use in a variety of applications, including biomedical 
imaging and drug delivery, has led to concern about the potentially hazardous impacts 
on human health.  Mast cells are critical for innate and adaptive immune responses, 
often modulating allergic and pathogenic conditions, including pulmonary and 
cardiovascular diseases.  Mast cells are well known to act in response to danger signals 
through a variety of receptors and pathways including IL-33 and the IL-1 like receptor 
ST2.  The aim of this study was to investigate involvement of mast cells and the IL-
33/ST2 axis in the pulmonary and cardiovascular toxicities induced by engineered multi-
walled carbon nanotubes (MWCNTs) following oropharyngeal aspiration.  We assessed 
inflammatory, fibrotic, and functional responses in the lung, as well as cardiac ischemia-
reperfusion (IR) injury responses in C57BL/6, KitW-sh (mast cell deficient), KitW-sh 
reconstituted with either wild-type or ST2-/- mast cells, and ST2-/- deficient mice.  Mice 
with a sufficient population of mast cells (C57BL/6 and reconstituted KitW-sh mice) 
exhibited significant pulmonary inflammation, exhibited by increased neutrophils and 
associated with elevated IL-33, impaired pulmonary function, increased granuloma 
formation, and collagen deposition 30 days following exposure to MWCNT.  
Additionally, exacerbation of myocardial infarction was observed in the same groups of 
mice 1 day following MWCNT exposure.  These toxicological effects of MWCNTs were 
observed only in mice with a sufficient population of mast cells and were not observed 
when mast cells were absent or incapable of responding to IL-33 (KitW-sh, KitW-sh
reconstituted with ST2-/- mast cells or ST2-/- mice).  These findings establish for the first 
time, an unrecognized, but critical role for mast cells and the IL-33/ST2 axis in 
orchestrating adverse pulmonary and cardiovascular responses to an engineered 
nanomaterial, giving insight into a previously unknown mechanism of toxicity.  In 
identifying the importance of the IL-33/ST2 axis and mast cells in this novel mechanism 
of toxicity, our study provides a means of addressing current concerns regarding 
nanoparticle exposures and the safety of engineered nanomaterials for use in 
biomedical applications in identifying a realistic therapeutic target for potential 
nanoparticle induced toxicities.   
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CHAPTER 1:  INTRODUCTION 
Nanomaterials 
In recent years, nanomaterials have become more prominent in a variety 
industries and applications.  The Project of Emerging Nanotechnologies identifies a 
521% increase in inventory of nanotechnology-based products from 2006 to 2011 (The 
Project, 2012).  Currently, the United States, ahead of Europe and East Asia, 
demonstrates an inventory of over 500 nanoparticle containing consumer products, an 
increase from less than 150 products in 2006 (The Project, 2012).  Consumer products 
containing nanomaterials fall into a variety of categories including health and fitness, 
automotive, food and beverage, electronics, and applicances, all of which have 
exhibited a rise in the number of products from 2006 to 2011 (The Project, 2012).  
Increased interest in nanoparticles, such as carbon nanotubes (CNTs), is due to their 
unique physical and chemical properties including high mechanical strength, high 
electrical conductivity and lightweight structure (Ajayan et al., 1999; Endo et al., 2008b; 
Lin et al., 2004).  These characteristics have made CNTs ideal for use in conductive 
and high-strength composites, sensors, energy conversion devices, drug delivery 
systems, as well as other biomedical applications (Baughman et al., 2002; Martin and 
Kohli, 2003).   
In the innovative arena of drug delivery, CNTs are being utilized as carriers of a 
variety of therapeutics.  As many drugs are associated with limited bioavailability, 
solubility and selectivity, resulting in an abundance of adverse effects, CNTs provide a 
new approach to improve the pharmacokinetic aspects of a drug.  By functionalizing 
CNTs with specific peptides, for example, can increase affinity for receptors, by 
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enabling greater intracellular localization for a peptide that normally has low cellular 
uptake (Bianco et al., 2005).  CNTs can be functionalized in numerous ways not only to 
enhance drug delivery but also to target antigen presentation and gene delivery.  The 
addition of antigens to a CNT carrier can be used to elicit a specific immune response 
through numerous immune cell types to generate antigen-specific antibodies (Bianco et 
al., 2005).  CNTs are advantageous in this regard as no antibodies are produced in 
response to the carrier, demonstrating a unique and promising method of vaccine 
delivery (Lin et al., 2004; Bianco et al., 2005).  Gene therapies also show great promise 
in the treatment of cancers, genetic disorders and other diseases, but are administered 
through a viral vector, which often results in undesired immune responses (Bianco et 
al., 2005).  The use of CNTs as non-viral vectors in gene therapy allows for an alternate 
means of delivery that is specific to DNA bio-interactions (Bianco et al., 2005).  The 
means by which CNTs may enhance and contribute to any given application 
demonstrates the potential for CNTs in several fields, and is evident in the novel 
applications of drug delivery.  
While the use of CNTs may be advantageous in many disciplines, there is cause 
for concern as the potential health hazards are not fully understood.  The means of 
exposure to CNTs can be intentional (e.g. drug delivery) or unintentional (environmental 
or occupational) and is currently unregulated in most industries and countries.  
Therefore, it is of great interest to further examine CNT toxicity and the implications on 
human health and safety.  
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Carbon Nanotubes  
Multi-walled carbon nanotubes (MWCNTs), a particular type of CNT, are widely 
used and as a result, have been the subject of multiple investigations regarding their 
potential toxicity.  Several studies have identified that MWCNT exposure induces 
adverse cardiovascular and pulmonary effects including: inflammation, fibrosis and 
altered lung function.   
 
CNT Induced Pulmonary Toxicity 
Exposure to MWCNTs has been shown to elicit cytotoxic responses in several 
cell types found in the lung (Cavallo et al., 2012; Di Giorgio et al., 2011).  In cultured 
human lung epithelial cells, one of the first cell types likely to encounter inhaled 
particulates, exposure to MWCNT resulted in decreased cell viability as demonstrated 
by an increased lactate dehydrogenase (LDH) release, a marker of cell cytotoxicity and 
cell membrane integrity (Cavallo et al., 2012).  The damage to cell membranes induced 
by MWCNTs was evident in scanning electron microscopy (SEM) images, which 
displayed internalization of MWCNT by lung epithelial cells and compromised 
membrane integrity leading to cell death (Cavallo et al., 2012).  Similarly, macrophages 
exposed to MWCNT in vitro exhibited cytotoxicity, particularly though necrosis (Di 
Giorgio et al., 2011).  MWCNTs not only induce cytotoxicity that results in the release of 
mediators, they initially stimulate both pulmonary epithelial cells and macrophages to 
produce pro-inflammatory mediators such as TNF-α (Di Giorgio et al., 2011).   
Moreover, the size-associated aspects of nanomaterials also accentuate the 
biopersistance of nanoparticles and evasion of clearance mechanisms.  The shape and 
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length of CNTs predispose them to increased retention time within tissues prior to 
clearance.  Retention of CNT fiber in the murine pleural space, for example, was shown 
to be length dependent (Murphy et al., 2011).  Furthermore, due to their length and 
fiber-like dimensions, CNTs have been shown to negatively impact macrophages which 
internalize MWCNTs through unsuccessful phagocytosis of the particles in their entirety, 
displaying numerous penetrations sustained out to 56 days and likely responsible for 
the production of reactive oxygen species (ROS) associated with MWCNT exposure (Di 
Giorgio et al., 2011; Mercer et al., 2010; Murphy et al., 2012; Ryman-Rasmussen et al., 
2009a).  The development of pulmonary inflammation following MWCNT exposure has 
been shown to manifest through the infiltration of immune cells, like macrophages and 
neutrophils, as well as the production of pro-inflammatory cytokines and chemokines 
(Aiso et al., 2010; Han et al., 2010).  Specifically, exposure to MWCNT has been 
reported to result in the activation of numerous pulmonary cell types and the 
subsequent production of pro-inflammatory cytokines including interleukin (IL)-1β, IL-6, 
IL-33 and osteopontin (OPN) (Inoue et al., 2009; Katwa, in submission 2012; Wang et 
al., 2011a).   
In addition, mice sensitized to ovalbumin (OVA) and subsequently exposed to 
MWCNT demonstrated significant pulmonary neutrophil infiltration and increased 
cytokine expression including IL-5 and IL-13, affirming the ability of MWCNTs to 
potentiate allergic responses in mouse models of asthma (Ryman-Rasmussen et al., 
2009b).  In asthma, the presence of certain T helper (Th) 2 cytokines such as IL-13 can 
further enable the release of other cytokines, which directly modulate aspects of the 
disease.  In animal models of asthma, the release of IL-13 by mast cells and other cell 
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types has been shown to induce airway hyperreactivity by activating receptors on 
airway smooth muscle cells (ASMC) (Brightling et al., 2003b).  MWCNTs can also 
augment pre-existing pulmonary inflammation induced by initial lipopolysaccaride (LPS) 
activation of the immune response (Inoue et al., 2008).  These MWCNT induced 
inflammatory responses are further supported by increased numbers of neutrophils 
within bronchoalveolar lavage fluid (BALF) and lung tissue, observed as early as 24 
hours and persisting for up to 30 days post-exposure (Kim et al., 2010; Porter et al., 
2010).   
Doses of MWCNTs comparable to those observed in human exposure levels 
have been shown to elicit pulmonary fibrotic responses as early as 7 days post-
exposure as exhibited by increased collagen deposition, development of granulomas 
and fibrosis in murine lungs (Porter et al., 2010).  As MWCNTs elicit pulmonary 
inflammatory cell recruitment, macrophages and other cell infiltrates are known to 
contribute to the composition of pulmonary granulomas observed as early as 30 days 
following exposure (Wang et al., 2011a).  The development of fibrotic tissue resulting 
from MWCNT exposure has also been associated with increased production of platelet 
derived growth factor AA (PDGF-AA) by macrophages and epithelial cells (Cesta et al., 
2010).  Data from several other studies also demonstrate granulomatous and fibrotic 
tissue formations at 30, 60 and 90 days following MWCNT exposure (Huizar et al., 
2011; Ma-Hock et al., 2009; Wang et al., 2011a).  Several other pro-fibrotic mediators 
are known to be involved in MWCNT mediated fibrosis.  Despite its role in asthmatic 
responses, IL-13, along with PDGF-AA and transforming growth factor (TGF-β) is 
considered a fibrogenic mediator (Ryman-Rasmussen et al., 2009b).  IL-13 has been 
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reported to upregulate TGF-β and stimulate its production in pulmonary macrophages 
and epithelial cells (Lee et al., 2001).  Furthermore, it can also upregulate PDGF-AA to 
induce the growth and proliferation of lung fibroblasts, the primary cell type responsible 
for collagen deposition within lung tissue and the morphological changes observed in 
the pathogenesis of fibrotic diseases (Ingram et al., 2004).  As with pulmonary 
inflammation, pre-existing allergic conditions may prime the immune system to also 
augment pulmonary fibrotic responses including increased deposition of collagen and 
exacerbation of airway fibrosis, as seen in mice sensitized with OVA following MWCNT 
inhalation (Ryman-Rasmussen et al., 2009b).   
 
CNT Induced Cardiovascular Toxicity 
The toxicity of MWCNT on the cardiovascular system is largely unknown; 
however, some recent in vitro studies have suggested adverse effects on cell viability, 
permeability, migration and ROS generation in endothelial cells (Pacurari et al., 2012; 
Walker et al., 2009).  Specifically, endothelial cells exposed to MWCNTs demonstrated 
increased LDH and IL-8 release, mediators indicating cytotoxic responses (Pacurari et 
al., 2012).  In addition, the functionality of endothelial cells was reported to have been 
compromised due to altered vascular endothelial-cadherin localization, formation of 
stress fibers and disrupted actin cytoskeleton structures coupled with decreased tubule 
formation, in the presence of MWCNTs (Walker et al., 2009).  It has also been reported 
that the observed changes in cytoskeleton structures are a result of ROS generation, 
well known to result in endothelial dysfunction (Pacurari et al., 2012). These factors are 
especially important in maintaining the integrity of endothelial cells, which act as barrier 
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cells in the cardiovascular system.   In vivo, MWCNTs have been shown to exacerbate 
Ischemia Reperfusion (IR) injury response as early as 1 day post-exposure, 
demonstrating a potential for MWCNTs to modulate pre-existing cardiovascular 
conditions(Urankar, in submission 2012a). 
 
IL-33 
IL-33 is a novel cytokine belonging to the IL-1 superfamily and has recently been 
termed an “alarmin” for its ability to alert the immune system during injury (Moussion et 
al., 2008; Schmitz et al., 2005).  Known to play a role in both innate and adaptive 
immune responses, IL-33 has been described as a mediator in several disease 
pathologies including fibrosis, asthma, allergic responses, anaphylaxis and 
cardiovascular disease (Haraldsen et al., 2009; Liew et al., 2010).  Like other alarmins, 
also known as endogenous danger signals, IL-33 activates immune cells and 
subsequent inflammatory processes in response to cellular trauma or necrosis through 
a receptor mediated signaling pathway (Kono and Rock, 2008).  As shown in Figure 1.1, 
IL-33 is able to impart its numerous cellular effects through binding to its receptor ST2, 
which is known to heterodimerize with the IL-1 receptor accessory protein (IL-1RAcP) 
(Chackerian et al., 2007).  Upon activation of the ST2 receptor, propagation of signal 
transduction is induced by recruitment of Myeloid differentiation primary response gene 
88 (MyD88), IL-1R-associated kinase (IRAK) 1, IRAK4 and TRAF6 to the ST2/IL-1RAcP 
receptor complex (Figure 1.1) (Schmitz et al., 2005; Suzuki et al., 2002).  Many of these 
recruited adaptor proteins are central to the signaling of the IL-1 superfamily of 
cytokines (Janssens and Beyaert, 2002).  Downstream signaling of the ST2 receptor 
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leads to the activation of the mitogen-activated protein kinases (MAPKs) and nuclear 
factor κB (NF-κB), proteins known to modulate transcription of numerous Th2 cytokines 
and subsequent immune responses (Figure 1.1) (Gadina and Jefferies, 2007).  
Furthermore, several studies have indicated that the soluble ST2 receptor (sST2) acts 
as a decoy receptor by sequestering IL-33 and inhibiting additional stimulation of the IL-
33/ST2 signaling pathway shown in Figure 1.1, to reduce the resulting inflammatory 
responses in a negative feedback loop (Hayakawa et al., 2007; Palmer et al., 2008). 
IL-33 is acknowledged in not only initiating, but also in modulating immune 
responses.  The potential of IL-33 to carry out these functions is dependent upon its 
activity and has been a subject of great debate.   As a member of the IL-1 family of 
cytokines, it was initially believed to be processed by caspase-1 from a full length, pro-
IL-33 form to a mature, cleaved form, similar to IL-18 (Schmitz et al., 2005).  However, 
more recent studies have indicated that IL-33 may be regulated by other proteases such 
as neutrophil elastase, cathepsin G and neutrophil proteinase 3 (PR3) to yield an active 
mature IL-33 (Bae et al., 2012; Lefrancais et al., 2012; Zhiguang et al., 2010).  While full 
length IL-33 is biologically active, cleavage of IL-33 by these proteases results in a more 
active form, often secreted during an inflammatory response (Zhiguang et al., 2010).   
IL-33 has also been proposed to have dual functional roles, acting as a 
traditional, intracellular cytokine as well as a regulatory intra-nuclear cytokine 
(Haraldsen et al., 2009).  Intracellularly, IL-33 can be found constitutively co-localized to 
the nucleus in several cell types including endothelial and epithelial cells.  In endothelial 
cells, IL-33 has been found to act as a heterochromatin-associated nuclear factor, 
displaying transcriptional repressor properties, similar to high mobility group box 1 
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(HMGB1) and nuclear factor preferentially expressed in high endothelial venules (NF-
HEV) (Carriere et al., 2007).  Like HMGB1, IL-33 can also be released extracellularly 
during cellular necrosis or trauma (Luthi et al., 2009; Scaffidi et al., 2002).  This is in 
contrast to cells undergoing apoptosis, which retain IL-33 intracellularly (Luthi et al., 
2009).  It has been proposed that the function of IL-33 as an alarmin is centered on its 
release during cell injury, potentially facilitating disease pathologies (Oboki et al., 2011).   
 
IL-33/ST2 Pathway in Pulmonary Pathophysiology 
IL-33 has been implicated in a variety of pulmonary conditions.  In lung tissue the 
ST2 receptor was preferentially expressed in microvascular endothelial cells as well as 
airway epithelial cells, and was found to drive inflammation with the production or 
release of Th2 cytokines upon activation by IL-33 (Yagami et al., 2010).  It has also 
been reported that over-expression of IL-33 in a murine allergic asthma model displayed 
spontaneous pulmonary inflammation as evidenced by eosinophilic infiltration, goblet 
cell hyperplasia and an increase in inflammatory factors including IL-5, IL-8 and IL-13 
(Zhiguang et al., 2010).  Furthermore, linical studies report acute exacerbations in 
patients with asthma associated with increased levels of serum sST2 resulting from the 
activation of the IL-33/ST2 pathway (Oshikawa et al., 2001).  However, the role of IL-33 
in pulmonary pathophysiology is not strictly limited to allergic or inflammatory disease.  
Patients with systemic sclerosis, an autoimmune disease, demonstrate an association 
of increased serum IL-33 levels with the extent of pulmonary fibrosis (Yanaba et al., 
2011). 
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IL-33/ST2 Pathway in Cardiovascular Disease  
While some studies have examined the relationship between the IL-33/ST2 
pathway and adverse cardiovascular events, it remains largely unexplored.  However, 
IL-33 has been shown to activate endothelial cells to promote angiogenesis and 
vascular permeability through the IL-33/ST2 pathway signaling molecule TNF receptor 
associated factor (TRAF) and subsequent activation of the PI3K/Akt/eNOS pathway to 
mediate downstream nitric oxide (NO) dependent signaling (Choi et al., 2009).  
Moreover, IL-33 activation of the PI3K/Akt/eNOS pathway resulting in NO production is 
necessary for the facilitation of both vascular permeability, crucial for infiltration of mast 
cells, and angiogenesis, a physiological event that is pivotal in development, wound 
healing and inflammatory diseases (Folkman, 1995).   Clinically, elevated levels of sST2 
have been observed in patients who had experienced hospitalization, reinfarction, and 
heart failure, all of which were combined for a primary endpoint termed major adverse 
cardiac events (MACE) (Dhillon et al., 2011).  Further analysis exhibited a potential for 
sST2 to be a predictor of left ventricle functional recovery, reinfarction and mortality 
following myocardial infarction (Dhillon et al., 2011; Weir et al., 2010).  Further study is 
required to delineate IL-33 involvement in the cardiovascular system and potentially 
adverse cardiac events. 
 
IL-33 Targets  
It is well established that IL-33 targets a variety of cell types including 
macrophages, eosinophils, basophils and epithelial, endothelial, dendritic, T, and mast 
cells (Oboki et al., 2011).  As a key player in several immune pathways, the activation of 
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the ST2 receptor by IL-33 on several immune cells including mast cells has been shown 
to induce the release of a variety of Th2 pro-inflammatory cytokines such as IL-6 and IL-
13 (Enoksson et al., 2011).  In particular, mast cells, one of the few cell types to highly 
express the ST2 receptor, release a host of cytokines including IL-1β, IL-6, IL-13, MCP-
1 and TNF-α following activation via the ST2 receptor (Iikura et al., 2007; Moulin et al., 
2007).  Therefore, mast cells may be key players in many IL-33/ST2 pathway mediated 
immune responses or disease pathologies.   
 
Mast Cells 
Mast Cell Growth and Differentiation 
Mast cells develop from CD34+/CD117+ (c-Kit+) hematopoietic stem cells that 
originate in the bone marrow (Kirshenbaum et al., 1991).  While these pluripotent 
hematopoetic stem cells may also give rise to basophils, hematopoietic stem cells, 
unlike many involved in myeloid and lymphoid differentiation, do not down-regulate c-Kit 
receptor expression.  Therefore, in the presence of stem cell factor (SCF), a ligand for 
the c-Kit receptor, progenitor cells differentiate and mature within various tissues as 
mast cells (Brown et al., 2008).  Another cytokine known to promote growth of mast 
cells is IL-9.  IL-9, along with SCF, has been shown not only to increase mast cell 
growth and promote the release of mast cell progenitors from bone marrow, but also to 
facilitate the production of mast cell proteases and other cytokines (Matsuzawa et al., 
2003; Wiener et al., 2004).  Mast cell maturation and migration from the peripheral 
vasculature into tissues requires the influence of several mediators including IL-3, α4 
integrins and vascular cell adhesion molecule-1 (VCAM-1).  Mast cell recruitment to the 
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lung, for example, is dependent upon expression of α4β1 and α4β7 integrins, which are 
able to interact with pulmonary endothelial VCAM-1 to enable migration into lung tissue 
(Abonia et al., 2006).  In addition, the chemokine receptor CXCR2 is known to modulate 
the expression of VCAM-1 and is required for proper migration of mast cell progenitors 
to host tissues (Hallgren et al., 2007).     
 
Mast Cell in Host Tissues 
 Mast cells are found in a variety of tissue types and easily distinguished by the 
metachromatic staining of their granules, as first discovered by the scientist Paul Erlich 
(Beaven, 2009).  In humans, they are most commonly known to reside around mucosal 
membranes and connective tissues and thus found in higher density in tissues of the 
gastrointestinal tract and skin (Yong, 1997).  However, mast cells do exist in most tissue 
types including the stomach, colon, lymph nodes, brain, heart and lungs (Ghanem et al., 
1988; Weidner and Austen, 1991).  They are found in the thalamus, hypothalamus, and 
various nuclei of the brain, as mast cell mediators have been known to impact neuronal 
responses as well as vascular function, altering permeability of the blood-brain barrier 
(Wilhelm et al., 2005; Zhuang et al., 1996; Zhuang et al., 1997).  Mast cells have long 
been identified in cardiac and arterial tissues, but the potential role of mast cells in the 
cardiovascular system has been elusive until recent years wherein cardiac mast cells 
have been implicated in several pathophysiological conditions (Bot et al., 2007; Dvorak, 
1986; Ghanem et al., 1988; Gilles et al., 2003).  Similarly, mast cells have been known 
to be involved in several pulmonary pathophysiological conditions and are able to 
modulate immune responses due to their anatomical locations.  In the lung, mast cells 
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reside throughout the lung parenchyma, in the surrounding connective tissue, as well as 
in the mucosal regions of the respiratory tract (Patterson and Suszko, 1971).  The close 
proximity of mast cells to the smooth muscle layer within the respiratory tract ideally 
positions them to be able to influence airway hyperreactivity in the pathology of asthma 
as will be discussed later in greater detail (Brightling et al., 2003b).  As is evident with 
asthma, mast cells are able to contribute to several disease pathologies due to their 
unique locations in certain tissues.     
 
Mast Cells Phenotypes 
 There are two commonly recognized phenotypes of mast cells, which are 
delineated by their protease contents.  Mast cells that only contain tryptase are referred 
to as the MCT phenotype, while mast cells that contain tryptase, chymase, 
carboxypeptidase and cathepsin G are denoted as the MCTC phenotype (Pejler et al., 
2009).  A third phenotype, MCC, defined by mast cells that only contain chymase, has 
also been reported, though not often identified in tissues (Bradding et al., 1995).  In the 
human lung, MCTC, the phenotype generally associated with connective tissue mast 
cells, have been predominantly seen in pulmonary vessels and the pleura (Andersson 
et al., 2009).  In contrast, the MCT mucosal phenotype mast cells were discovered in 
higher proportion near the epithelium of the conducting airways, as well as throughout 
the lung parenchyma (Andersson et al., 2009; Schwartz et al., 1987).   The 
heterogeneity of mast cells throughout the human body, currently characterized by 
protease content into the MCT and MCTC phenotypes, can be further categorized in 
numerous ways due to varying attributes within phenotypes.  While the identification of 
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specific proteases within mast cells is a widely accepted means of phenotype 
classification, it is also understood that mast cell phenotype is driven by the 
microenvironment.   
 Mast cells are able to respond to mediators in their microenvironments that 
contribute to a specific phenotype.  Cord blood derived mast cells cultured with IL-4 and 
Th2 cytokines in addition to the required mast cell growth factor, SCF, demonstrated a 
MCTC connective tissue phenotype in vitro (Hsieh et al., 2005).  However, when co-
cultured with human airway epithelial cells, the mast cells, originating with a MCTC 
phenotype, eventually developed a MCT phenotype (Hsieh et al., 2005).  Classically, 
mast cells with a MCT phenotype have been known to develop an eicosanoid phenotype 
resulting in increased cys-leukotrienes or (cys-LT) production, classically enhanced 
following IgE-dependent activation.  However, in culture, mast cells were only able to 
display an eicosanoid phenotype following IgE-dependent high affinity IgE receptor 
(FcεRI) stimulation and priming with IL-4 and other Th2 cytokines (Hsieh et al., 2005).  
In addition to epithelial cell derived Th2 cytokines, SCF expression by epithelial cells 
has been shown to directly impact mast cell survival in co-cultures in vitro.  Thus 
epithelial cells may play a significant role in directing mast cell mediated responses, 
potentially through the expression of SCF (Hsieh et al., 2005).  Similarly, it has been 
proposed that endothelial cells may regulate mast cell function as both cell types in 
close proximity to connective tissues of blood vessels.   In the presence of pro-
inflammatory factors such as TNF-α, endothelial cells also upregulate SCF factor, 
promoting mast cell survival and proliferation (Konig et al., 1997).  Furthermore, 
increases in mast cell number were observed in co-culture systems with endothelial 
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cells, as wells as increases in VCAM-1 and E-selectin, enabling mast cell adhesion 
(Mierke et al., 2000).  Mast cells display great phenotypic plasticity and the 
microenvironments driving these mast cell phenotypes contribute greatly to mast cell 
function in specific biological compartments.    
 
Mast Cells in Lung Immunology 
Mast Cells in Innate Immunity 
 Mast cells play an important role as key effector cells in innate immunity.  Once 
activated, mast cells serve to regulate functions of other effector cells including dendritic 
cells and neutrophils, which act to propagate an innate immune response or to bridge 
the gap between innate and adaptive immunity, as is the case with dendritic cells.  The 
release of TNF-α and IL-1 by mast cells has been shown to induce chemotaxis and 
differentiation of dendritic cells and neutrophils to a targeted location of infection or 
inflammation (Cumberbatch et al., 2001; Zhang et al., 1992).  Other mediators released 
from mast cells, such as histamine, stimulate antigen presentation by dendritic cells 
through increasing expression of the major histocompatibility complex (MHC) class II 
molecules and facilitate further release of cytokines like MCP-1 to recruit additional 
immune cells and potentially activate the adaptive immune system (Caron et al., 2001).  
 During an innate immune response, the activation of mast cells and the release 
of their mediators can occur through several pathways.  It has long been established 
that mast cells have the ability to directly bind and phagocytose or opsonize pathogens.  
In doing so, mast cells have been shown to process pathogenic proteins and act as 
antigen presenting cells to T lymphocytes to further facilitate the immune response 
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(Frandji et al., 1996; Malaviya et al., 1996).  Another important facet of mast cell 
function in innate immunity and host defense is the ability of mast cells to recognize 
numerous pathogens as well as endogenous danger signals through the direct 
activation of pathogen associated molecular pattern (PAMP) receptors such as toll-like 
receptors (TLRs), scavenger receptors and several others.  The TLRs belong to the IL-1 
superfamily of receptors, many of which are expressed on mast cells (McCurdy et al., 
2003; Varadaradjalou et al., 2003).  Activation of the various TLRs enables the release 
of specific cytokine or chemokine profiles, formulating differential immune responses to 
the particular pathogenic or to the endogenous insults at hand.  Additionally, mast cells 
can also be activated through the complement system, traditionally initiated when C1 
complement factors bind to IgG-antigen or IgM-antigen complexes to propagate 
opsonization, chemotaxis and other means of fighting infection.  Mast cells not only play 
a role in bacterial infections, but similarly in parasitic and viral infections, acting as 
sentinels of the innate immune system (Marshall, 2004). 
 
Mast Cells in Adaptive Immunity 
 Though historically viewed as cells of the innate immune system, mast cells are 
often associated with Th2 responses and adaptive immunity due to their classical 
activation and degranulation through antigen-dependent crosslinking of the high affinity 
IgE receptor, FcεRI.  This allergic response results from the release of preformed 
mediators, such as proteases, cytokines, and chemokines, from the granular stores 
within mast cell (Metcalfe et al., 2009).  This early response is then followed by a late 
response four to six hours later wherein mast cells synthesize additional mediators for 
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further release (Tkaczyk et al., 2006).  The mast cell can also be activated through other 
immunoglobulin receptors, such as the high affinity IgG receptor (FcγRI) known to bind 
monomeric IgG1 and IgG3 isoforms with high affinity, in the presence of interferon-γ 
(IFN-γ).  With IFN-γ stimulation, it has been demonstrated that human mast cells 
express higher levels of FcγRI and that aggregates of FcγRI are capable of inducing 
mast cell degranulation and enhancing cytokine release indcluding TNF-α, IL-3, IL-4, IL-
13 and GM-CSF (Okayama et al., 2000).  Interestingly, it has also been shown that 
aggregation of IgG1, unlike IgG3 aggregates, can still activate FcγRI on mast cells to 
elicit degranulation, and that subsequent IgG complexes can initiate C3a formation to 
synergistically facilitate mast cell activation through the C3a G-protein coupled receptor 
(GPCR) expressed on mast cells (Ali et al., 2000; Woolhiser et al., 2004). 
 Along with immunoglobulin receptor activation, mast cells are able to modulate 
another key function of adaptive immunity through antigen presentation.  Like most cell 
types, mast cells express MHC class I, and are able to process bacterial antigens and 
present to T cells for further clonal expansion (Malaviya et al., 1996).  While not 
constitutively expressed, MHC class II expression can be induced in mast cells via TNF-
α or γ-IFN stimulation, enabling antigen presentation to T cells (Frandji et al., 1996).  
These mast cell and T cell interactions are supported by the mast cell expression of the 
co-stimulatory molecule OX40 ligand (OX40L), known to be involved with T cell 
proliferation and polarization (Kashiwakura et al., 2004; Ohshima et al., 1998).  The 
ability of mast cells to express OX40L also enables interactions with B cells and has 
been shown to induce B cell production of IgE in the presence of IL-4, thus driving many 
allergic and Th2 responses (Gauchat et al., 1993; Yoshikawa et al., 2001).  The 
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production of IgG1 by IL-4 stimulated B cells can also be facilitated by mast cell 
protease I (Yoshikawa et al., 2001).  With the release of cytokines such as IL-4 and IL-
13, mast cells can influence the polarization of naïve T helper cells.    
 Another cell type crucial to an adaptive immune response is the dendritic cell.  
The dendritic cell is foremost an antigen presenting cell, expressing high levels of MHC 
class II at full maturity following exposure to an antigen.  Investigation of mast cell and 
dendritic cell interactions has provided evidence suggesting mast cell components such 
as TNF, IL-1, prostaglandin E2 (PGE2) propagate dendritic cell migration and maturation 
(Cumberbatch et al., 2001; Kabashima et al., 2003).  While inducing the maturation of 
dendritic cells, PGE2 has also been shown to promote the transformation of these cells 
into the DC2 phenotype, which can facilitate a Th2 shift in T cell phenotype (Kalinski et 
al., 1997).  Thus mast cells can either directly or indirectly influence the polarization of 
naïve T cells to favor an adaptive immune response.   
  
Activation Pathways 
 Mast cells, known to have diverse functions in both innate and adaptive 
immunity, can be activated through a variety of means.  One of the most common and 
best-studied mechanisms of mast cell activation is the crosslinking of the high affinity 
IgE receptor, FcεRI, by IgE and antigen, leading to an adaptive immune driven Th2 
response.  The binding of antigen-IgE complexes to FcεRI initiates a signal transduction 
pathway beginning with the phosphorylation of the FcεRI cytosolic domains, 
immunoreceptor tyrosine-based activation motifs (ITAMs), and eventually leading to 
downstream activation of phospholipase C (PLC) isoforms, resulting in calcium release 
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through store operated calcium channels in the endoplasmic reticulum, and eventually 
degranulation of the mast cell (Metcalfe et al., 2009).  This activation pathway is a 
feature of type I hypersensitivity or allergic responses, largely driven by mast cell 
activation and the release of preformed mediators such as proteases and cytokines 
from cytoplasmic granules during degranulation (Metcalfe et al., 2009).   
 Mast cells are also involved in innate immune responses, several of which are 
initiated by alternative activation pathways including the TLRs, scavenger receptors and 
other PAMP receptors.  The TLRs are a family of receptors that are specific to the 
binding of different pathogen components.  In the case of TLR-4, binding of specific 
pathogen components, such as LPS from gram-negative bacteria, activates the mast 
cell and promotes release of cytokine profile specific for the receptor (Varadaradjalou et 
al., 2003).   
 An additional mast cell induced innate immune response to pathogen is the 
activation of mast cells through the complement system.  Though the complement 
system itself plays an important role in host defense of bacterial infections through 
opsonization and chemotaxis of other effector cells, it is also known for its ability to 
activate mast cells.  Complement factors, particularly C3 and C4 proteins of the 
classical pathway, have been shown to be crucial in mast cell activation, as mice 
deficient in C3 and C4 proteins displayed significantly reduced degranulation.  When 
reconstituted with human C3 proteins, C3-/- mice in a model of bacterial infection 
exhibited levels of mast cell degranulation and cytokine release comparable to wild type 
animals (Prodeus et al., 1997).  Activation of mast cells by C3a and C5a complement 
proteins occurs through the corresponding GPCR expressed by the mast cell, initiating 
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the phospholipase C or phosphoinositide 3 kinase (PI3K) signaling cascades to mobilize 
calcium for degranulation and stimulate cytokine or chemokine production (Ali et al., 
2000).  Activation of the complement pathway can also be simultaneously stimulated by 
the binding of IgG to a mast cell IgG receptor FcγRIII, resulting in direct opsonization of 
pathogens by bacteria and triggering of the classical complement pathway with mast 
cell activation and subsequent initiation of the inflammatory cascade, both facilitated 
through the C3 complement protein (Baumann et al., 2001).   
 Mast cells are recognized as quintessential elements of the innate and adaptive 
immune systems.  Thus, the activation pathways of mast cells may also be 
indispensable to both types of immune response.   The activation of mast cells by IL-33 
and the ST2 receptor may occur as an innate or adaptive immune response, as the 
cytokine itself has been shown to mediate pathogenic conditions involving both 
(Haraldsen et al., 2009; Liew et al., 2010).  As previously described, IL-33 initiates 
activation of the mast cell through its receptor, ST2.  Upon binding of its ligand, the ST2 
receptor dimerizes with IL-1RAcP to begin recruitment of adaptor proteins and 
propagate signal transduction downstream to promote synthesis of pro-inflammatory 
cytokines and other mediators imperative to mast cell activation during an immune 
response (Chackerian et al., 2007; Schmitz et al., 2005; Suzuki et al., 2002).  
 Activation of the mast cell can facilitate the aforementioned effector cell 
functions, such as opsonization or clearance of pathogens or release of mediators to 
induce vascular permeability, smooth muscle cell contraction or even collagen 
deposition by fibroblasts.  However, it is prudent to recognize that activation of mast 
cells can also facilitate immunomodulatory functions of the mast cell described 
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previously.  Through the release of certain mediators, mast cells can influence other 
immune cells to increase chemotaxis, maturation and differentiation.  They can also 
present antigen to T-cells and promote immunoglobulin production by B-cells, 
particularly IgE (Gauchat et al., 1993).  These functions are positive modulators of 
immune function, however, mast cells also possess negative immunomodulatory 
functions, most commonly by means of IL-10 production leading to immunosuppression; 
thus establishing mast cells as important regulators of the immune system (Frossi et al., 
2010).   
 
Mast Cells and Pulmonary Disease 
Mast Cells in Asthma 
 Mast cells have been known to play a role in several pulmonary diseases 
including asthma and fibrosis.  Asthma is defined by thickening of the basement 
membrane, airway hyperresponsiveness, and eosinophilic airway inflammation resulting 
in the release of Th2 cytokines; all responses which can be notably impacted by mast 
cells (Alkhouri et al., 2011).  The symptoms and pathology of asthma, with the exception 
of airflow obstruction and airway hyperresponsiveness, are almost identical to those of 
eosinophilic bronchitis (Brightling et al., 2002).  Additionally, significant infiltration of 
mast cells in the ASMC layers is found in asthmatic patients and markedly absent in 
patients with eosinophilic bronchitis or normal healthy individuals (Brightling et al., 
2003a).  Mast cell implication in the pathophysiology of asthma is mainly centered on 
the presence and location of mast cells in the lung tissue as well as the mediators they 
release.  Mast cells are known to release Th2 cytokines such as IL-4 and IL-13, which 
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have been shown to contribute to airway inflammation during asthma through activation 
of receptors on ASMCs specific for these cytokines (Brightling et al., 2003b).  The ability 
of mast cells to modulate airway smooth muscle (ASM) is further enhanced by co-
localization in the ASM during asthma (Brightling et al., 2003b).  The ASM can also 
secrete mediators to stimulate migration of immune cells, particularly mast cells, with 
the release of chemotactic factors such as CXCL10 and CX3CL1 (also known as 
Fractalkine or FKN) (Brightling et al., 2005; El-Shazly et al., 2006).  Both these 
mediators have been known to induce chemotaxis through the CXCR3, a chemokine 
receptor on mast cells, which demonstrates a significantly increased expression in 
asthmatics compared to non-asthmatics (Brightling et al., 2005; El-Shazly et al., 2006).   
 Several studies have investigated different mast cell phenotypes and the 
potential phenotype-specific release of mediators in contributing to the pathogenesis of 
asthma.  Increased numbers of mast cells found within ASMCs, previously identified as 
the MCT phenotype, have been associated with increased levels of tryptase mRNA and 
protein in BALF of asthmatic patients (Brightling et al., 2005; Brightling et al., 2002).  
Mast cell tryptase is known to potentiate ASM hyperresponsiveness, an important and 
distinguishing feature in asthma pathophysiology (Sekizawa et al., 1989).  It is important 
to note that the MCT mast cell phenotype is typically expressed within the lungs, 
particularly the submucosa and epithelium of normal, non-asthmatic subjects (Balzar et 
al., 2011).  In delineating mild and severe asthma, it was found that while mild 
asthmatics displayed this high infiltration of the normal MCT mast cell phenotype, severe 
asthmatics displayed lower levels of total mast cells with a switch to the MCTC 
phenotype, supported by a characteristic increase in carboxypeptidase CP3A and 
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prostaglandin D2 (PGD2) levels (Balzar et al., 2011; Lewis et al., 1982).  Despite this 
decrease in total mast cells in patients suffering from severe asthma, levels of tryptase 
remained high in these asthmatics as mast cells of the MCTC phenotype are known to 
produce 2-3 times more tryptase compared to MCT phenotypes (Balzar et al., 2011; 
Schwartz et al., 1987).  Unlike many tissue types, which exhibited a reduction in the 
number of mast cells in severe asthmatics, the pulmonary epithelium continued to 
display increased mast cell numbers, suggesting that the epithelium may contribute to 
the differentiation and survival of the MCTC phenotype. 
 It has been suggested that epithelial cells may release mediators known to 
promote the development of the MCTC phenotype, such as TGF-β and other Th2 
cytokines (Balzar et al., 2011; Veldhoen et al., 2008).  Thus, the location of mast cells, 
their phenotypes, as well as mediators they release, are all aspects that contribute to 
the pathogenesis of asthma. 
 
Mast Cells in Pulmonary Fibrosis 
 Pulmonary fibrosis is often a characteristic of interstitial diseases and can 
manifest in several forms.  One of the most common forms of pulmonary fibrosis is 
idiopathic pulmonary fibrosis and is attributed to an unknown cause.  In pulmonary 
fibrotic conditions, an increase in mast cells has been identified and correlated with the 
degree of severity in fibrosis (Inoue et al., 1996; Pesci et al., 1993).  Furthermore, tissue 
taken from pulmonary fibrosis patients displayed mast cells in young interstitial and 
alveolar connective tissues containing fibroblasts, and were determined to have fewer 
granules present (Pesci et al., 1993).  The absence of normal numbers of granules 
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within mast cells suggests a correlation with increased levels of histamine, tryptase and 
other mast cell mediators found in BALF of patients with pulmonary fibrosis, often 
released during the process of chronic degranulation (Pesci et al., 1993).  Several mast 
cell mediators, including tryptase, basic fibroblast growth factor (bFGF) and chymase, 
have been implicated in advancing pro-fibrotic pulmonary pathologies.  The release of 
tryptase by mast cells has been shown to stimulate fibroblast proliferation and collagen 
synthesis through protease-activated receptor 2 (PAR-2) (Akers et al., 2000).   Like 
tryptase, bFGF is a mediator released by pulmonary mast cells and largely associated 
with lung fibrosis (Inoue et al., 1996).  Interestingly, bFGF release from the HMC-1 
human mast cell line was determined to be an IgE-independent mechanism as HMC-1 
cells lack complete and functional IgE receptors (Inoue et al., 1996).  Another important 
factor in mast cell mediated fibrosis is chymase.  Chymase is involved in modulating the 
pathogenesis of fibrosis partially through the activation of transforming growth factor 
beta (TGF-β), a pro-fibrotic mediator involved in the induction of fibrosis (Tomimori et 
al., 2003).   Bleomycin-induced fibrosis in rats was significantly increased as indicated 
by elevated collagen accumulation, but significantly diminished in the presence of a 
chymase inhibitor and in a mast cell deficient (i.e. Ws/Ws) rat strain (Tomimori et al., 
2003).  In addition, it has also been suggested that the pulmonary fibrotic toxicities 
induced by paraquat dichloride, a widely used herbicide, is also mediated through mast 
cell chymase activation of TGF-β and Angiotensin II (Ang II) (Lang et al., 2010; Orito et 
al., 2004).  The role of mast cell chymase has been established in the conversion of 
Ang I to Ang II in several tissue types including pulmonary tissue (Lindberg et al., 1997).  
Furthermore, Ang II induces a mitogenic response in human lung fibroblasts modulated 
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by TGF-β, facilitating pro-fibrotic conditions (Marshall et al., 2000).  These studies 
provide potential roles for mast cells and their mediators in modulating the pathogenesis 
of pulmonary fibrosis. 
 
Mast Cells and Environmental Exposures 
 The location of mast cells within various tissues has been proven to be pivotal in 
not only immune responses to pathogens, but also xenobiotic insults.  As discussed 
previously, mast cells play a distinct role in innate immunity, often acting as the first line 
of defense in pathogen recognition and subsequent initiation of host defense 
mechanisms.  Given the importance of mast cells in innate immunity, mast cells may 
also be critical immune cells in response to environmental exposures.  Respiratory 
exposures to ambient particles, diesel exhaust particles, asbestos, silica and C60 have 
all implicated the involvement of mast cells in the resulting immune responses. 
 
Ambient Particles 
 The adverse effects of ambient particulate matter (PM) are well known and have 
been reported to impact several physiological aspects including the respiratory system.  
Studies have shown a positive correlation between PM exposures and hospital visits for 
respiratory diseases including asthma and chronic obstructive pulmonary disease 
(COPD) (Atkinson et al., 2001; Peel et al., 2005).  Several pulmonary and immune cell 
types, such as alveolar macrophages and bronchial epithelial cells, have been 
implicated in the production of IL-6, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), macrophage inflammatory protein-1β (MIP-1β), monocyte chemotactic 
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protein-1 (MCP-1) and other pro-inflammatory mediators in response to PM exposure 
(Ishii et al., 2005).   In addition to these cell types, mast cells have been shown to play 
an important role in amplifying the PM induced inflammatory response (Alfaro-Moreno 
et al., 2008).  In vitro, co-cultures of macrophages, alveolar epithelial cells and 
endothelial cells demonstrate an increased granulocyte colony-stimulating factor (G-
CSF), MIP-1β, IL-8, and IL-6 production in the presence of mast cells (Alfaro-Moreno et 
al., 2008).  Of the mediators that are notably released, GM-CSF, G-CSF, MIP-1β and 
MCP-1 are well known to induce recruitment or proliferation of monocytes, 
macrophages and other granulocytes.  Therefore, mast cells may be an important 
component in the initiation and sustained recruitment of inflammatory cells to PM 
exposure.  As many of the adverse respiratory effects of PM exposure include asthma 
and other allergic responses, several studies have investigated mast cells in PM 
induced allergic responses.  Ambient PM in conjunction with airborne allergen exposure 
has been reported to exacerbate allergic asthmatic responses in mice potentiated by 
sustained mast cell activation (Jin et al., 2011).  Furthermore, organic dust exposed 
horses with equine heaves, similar to human occupationally or environmentally induced 
asthma, characterized with neutrophilic airway inflammation and obstruction, have 
demonstrated increased mast cell numbers in bronchial epithelium and tryptase 
production in BALF following an allergen challenge (Dacre et al., 2007).  
 
Diesel Exhaust 
 Urbanization in many countries throughout the world has resulted in the rise of 
motor vehicle generated air pollutants.  Diesel exhaust particles (DEP) contribute 
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significantly to the particulate matter emissions in urban areas, with particles that range 
from 20nm to 200nm in size, composed of hydrocarbons, metals, gases and other 
materials (Riedl and Diaz-Sanchez, 2005).  Several studies have examined the health 
effects of DEP exposures.  In healthy human volunteers from low particulate 
environments, BALF and bronchial tissue samples display neutrophil and mast cell 
infiltration, associated with increased pro-inflammatory mediators following short term 
DEP exposures (Behndig et al., 2006; Salvi et al., 1999).  Moreover, an increase in 
mast cell activation was observed with DEP exposure as determined by a rise in BALF 
methyl histamine, a mast cell specific mediator known to mediate endothelial cell 
permeability and most likely contributing to the observed inflammatory cell infiltrates in 
peripheral blood (Salvi et al., 1999).  In sensitized humans, DEP exposure augments 
allergic responses resulting in mast cell production of IL-4 and subsequently driving a 
Th2 response (Wang et al., 1999).  The exacerbated Th2 response with DEP and 
antigenic challenge has also been observed in mice, particularly resulting in allergic 
eosinophilic airway inflammation.   However, this response was notably absent in mast 
cell deficient mice, indicating the involvement of mast cells in mediating DEP 
inflammation and exacerbation of allergic responses (Ichinose et al., 2002).   
 
Asbestos 
 The inhalation of asbestos fiber has been well characterized to induce pulmonary 
inflammation, fibrosis, and mesothelioma (Mossman et al., 2011; Padilla-Carlin et al., 
2011).  In rats, intratracheal exposure to chrysotile asbestos fibers resulted in 
peribronchial pulmonary fibrosis and an increase in mast cells within or surrounding the 
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fibrotic tissue projections, associated with a subsequent increase of serotonin and 
histamine release, a response that is ablated in rats not exposed to chrysotile (Keith et 
al., 1987).  Similar data have been reported with crocidolite, amosite and anthophyllite 
asbestos fibers (Wagner et al., 1984).  While the exact role of mast cells in asbestos-
induced pulmonary toxicity is undefined, mast cells have been implicated in several 
pulmonary fibrotic diseases and thus may be involved in mediating the fibrotic toxicities 
observed following exposure to asbestos fibers.   
 
Silica 
 The inhalation of crystalline silica, most commonly through occupational 
exposures, results in the development of silicosis, an interstitial lung disease 
characterized by fibrotic nodules, inflammatory cell infiltrates, thickening of the alveolar 
interstitium and the production of pro-inflammatory mediators such as TNF-α, TGF-β 
and IL-1 (Vanhee et al., 1995).  Though the production of these cytokines has often 
been attributed to alveolar macrophages, mast cells have been shown to produce a 
similar array of mediators in the presence of silica including MCP-1, IL-13 and TNF-α 
(Brown et al., 2007).  Furthermore, it has been established that mast cells are able to 
modulate the pulmonary effects of silica through the activation of scavenger receptors 
(Brown et al., 2007).  In a clinical study, lung tissue of subjects occupationally exposed 
to silica not only demonstrated a significant increase in total pulmonary mast cells found 
to be near fibrotic nodules, but also found these mast cells to be positive for bFGF, 
correlating with the severity of fibrosis (Hamada et al., 2000).  Additional studies have 
reported similar results with increased mast cell numbers in acute and intermediary 
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lesions representative of various fibrotic remodeling stages (Delgado et al., 2006).  Mast 
cells may mediate the development of fibrosis and the remodeling of lung tissue through 
increased release and activity of mast cell proteases such as chymase, known to be 
involved in tissue remodeling and shown to decrease the severity of silica induced 
pulmonary toxicity when inhibited (Brown et al., 2007; Takato et al., 2011).  The role of 
mast cells in mediating the pulmonary toxicities of silica exposure include the induction 
of inflammation through the production of pro-inflammatory cytokines as well as the 
modulation of fibrotic tissue through the increase in protease activity. 
 
C60 
 C60 or fullerenes, like CNT and other engineered nanoparticles, can be 
functionalized and subsequently utilized in a plethora of applications such as drug 
delivery.  The potential for the use of C60 in the medical field is due primarily to the 
capability of adding modified side chain functional groups to permit greater 
biocompatibility and thus allow for use in the treatment of a variety of disease 
pathologies (Satoh and Takayanagi, 2006).  Interestingly, C60 has displayed uniquely 
favorable outcomes in modulating allergic responses for potential therapeutic purposes 
(Norton et al., 2010; Ryan et al., 2007).  Water-soluble derivatives of C60, like those 
with tetraglycolic acid or N-ethyl moieties, were able to inhibit mast cell cytokine 
production and degranulation, due to the trafficking of fullerenes in mast cell 
endoplasmic reticulum and subsequent inhibition of calcium release, required for FcεRI 
receptor-mediated degranulation (Dellinger et al., 2010; Norton et al., 2010; Ryan et al., 
2007).  In vivo, these fullerene derivatives were able to attenuate mast cell-driven 
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anaphylaxis reactions and possibly provide a means for targeting the activation of mast 
cells and subsequent release of mediators during allergic responses (Norton et al., 
2010; Ryan et al., 2007).     
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Goal of Research and Statement of Hypothesis 
 MWCNT have been shown to elicit pulmonary and cardiovascular toxicity 
including pulmonary inflammation, fibrosis, altered lung function, as well as exacerbated 
myocardial ischemia reperfusion injury.  While several studies have investigated the 
pulmonary and cardiovascular toxicities, few have examined the means by which 
MWCNT elicit such adverse responses and the underlying mechanisms have remained 
elusive.   
 The goal of this research project was to identify and evaluate the mechanism(s) 
of MWCNT induced pulmonary and cardiovascular toxicities.  Mast cells have previously 
been shown to mediate the toxicity of particles such as silica.  In addition, the role of 
mast cells in several pulmonary and cardiovascular pathophysiologies including 
inflammation, fibrosis, remodeling, and allergic disease, has been clearly established.  
Thus, it was essential to examine the potential involvement of mast cells in modulating 
the MWCNT induced adverse effects resulting in pathological conditions.  Furthermore, 
in elucidating the underlying mechanisms of toxicity, we identify a means of addressing 
the concerns of nanoparticle exposure, whether by alleviating adverse side effects of 
drug delivery systems that utilize MWCNT or by identifying targets of future therapeutics 
to treat MWCNT exposure.  The impact of this research could provide crucial insight into 
many of the issues that currently impact the fields of nanotoxicology and 
nanotechnology.    
 
Specific Aims 
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Aim 1: Evaluate the development of pulmonary inflammation and fibrosis following 
instillation of MWCNTs in C57BL/6 and mast cell deficient B6.Cg-KitW-sh mice.   
 
 This specific aim will compare expression of pro-inflammatory and pro-fibrotic 
cytokines, histological changes and pulmonary function as indicators of fibrosis between 
C57BL/6 and B6.Cg-KitW-sh mast cell deficient mice exposed to MWCNTs.  B6.Cg-KitW-sh 
mice reconstituted with bone marrow derived mast cells (BMMCs) will also be evaluated 
for the endpoints listed above to further confirm the differences between C57BL/6 and 
B6.Cg-KitW-sh mast cell deficient mice. 
 
Aim 2: Establish the role of IL-33 and ST2 facilitated activation of mast cells in MWCNT 
mediated pulmonary fibrosis.    
 
 This aim will test the hypothesis that MWCNT exposure results in an increase in 
lung epithelial production of IL-33, subsequent activation of mast cells through the ST2 
receptors, resulting in increases in pulmonary inflammatory and fibrotic responses.  
Knockout mice for IL-33 and ST2 will be used to investigate cytokine expression, and 
histological changes to determine the role of IL-33 in MWCNT induce fibrosis.   
 
Aim 3: Identify specific mechanism(s) of MWCNT induced activation of mast cells in 
vitro via IL-33.   
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 This aim will test the hypothesis that IL-33 activates mast cells via the ST2 
receptor to produce MWCNT induced adverse pulmonary fibrotic effects.  BMMCs will 
be co-cultured with IL-33 producing lung epithelial cells to further examine mast cell 
activation and subsequent release of pro-fibrotic mediators with exposure to MWCNT. 
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Figure 1.1 IL-33 and ST2 Receptor Signaling Pathway 
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CHAPTER 2:  MULTI-WALLED CARBON NANOTUBE INSTILLATION IMPAIRS 
PULMONARY FUNCTION IN C57BL/6 MICE 
 
PUBLISHED:  Wang X, Katwa P, et al. Particle and Fibre Toxicology 2011, 8:24 
 
SUMMARY 
Background: Multi-walled carbon nanotubes (MWCNTs) are widely used in many 
disciplines due to their unique physical and chemical properties. Therefore, some 
concerns about the possible human health and environmental impacts of manufactured 
MWCNTs are rising. We hypothesized that instillation of MWCNTs impairs pulmonary 
function in C57BL/6 mice due to development of lung inflammation and fibrosis.  
Methods: MWCNTs were administered to C57BL/6 mice by oropharyngeal aspiration 
(1, 2, and 4 mg/kg) and we assessed lung inflammation and fibrosis by inflammatory 
cell infiltration, collagen content, and histological assessment. Pulmonary function was 
assessed using a FlexiVent system and levels of Ccl3, Ccl11, Mmp13 and IL-33 were 
measured by RT-PCR and ELISA.  
Results:  Mice administered MWCNTs exhibited increased inflammatory cell infiltration, 
collagen deposition and granuloma formation in lung tissue, which correlated with 
impaired pulmonary function as assessed by increased resistance, tissue damping, and 
decreased lung compliance. Pulmonary exposure to MWCNTs induced an inflammatory 
signature marked by cytokine (IL-33), chemokine (Ccl3 and Ccl11), and protease 
production (Mmp13) that promoted the inflammatory and fibrotic changes observed 
within the lung.    
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Conclusions: These results further highlight the potential adverse health effects that 
may occur following MWCNT exposure and therefore we suggest these materials may 
pose a significant risk leading to impaired lung function following environmental and 
occupational exposures. 
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INTRODUCTION 
The use of nanomaterials has been prominent in recent years due to their 
diverse properties and applications.  Carbon nanotubes, in particular, possess the 
potential for numerous modifications and display unique physical and chemical 
properties, making them the ideal choice for product development in technological and 
biomedical industries (Martin and Kohli, 2003).  Despite increasing use of carbon 
nanotubes, there is limited research on the potentially detrimental effects to human 
health and safety.  In existing studies of carbon nanotube exposure in animal models, 
multi-walled carbon nanotubes (MWCNT) have been shown to potentiate allergic, 
inflammatory and fibrotic pulmonary responses.  These effects have been associated 
with significant increases in pro-inflammatory cytokines such as IL-5, IL-6, IL-33 and 
others (Inoue et al., 2009).  Inoue et al. determined that MWCNT exposure augments 
pulmonary inflammation induced by initial LPS activation of cytokines (Inoue et al., 
2008).  Post-exposure periods as early as 7 days have demonstrated increased 
collagen accumulation, development of granulomas and fibrosis in murine lungs 
exposed to MWCNT levels comparable to human exposure levels (Porter et al., 2010).  
Ma-Hock et al. showed similar data with MWCNT inhalation in rats 90 days post-
exposure (Ma-Hock et al., 2009).  Development of fibrotic tissue in lungs of mice 
exposed to MWCNT has been shown to correlate with increased macrophage and 
epithelial cell mediated production of platelet derived growth factor AA (PGDF-AA), a 
major mediator of pulmonary fibrosis (Cesta et al., 2010).  In addition to inducing 
adverse pulmonary effects, exposure to MWCNTs has also been shown to augment 
pre-existing allergic responses.  Ryman-Rassmusen et al. demonstrated that mice 
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exposed to MWCNT following ovalbumin sensitization developed significantly increased 
airway fibrosis and lung inflammation compared to mice that were not treated with 
MWCNTs but challenged with ovalbumin (Ryman-Rasmussen et al., 2009b).  This 
suggests that pre-existing allergic conditions may predispose individuals to adverse 
effects of MWCNTs (Ryman-Rasmussen et al., 2009b).  While these data validate the 
potential adverse effects, few studies have been conducted to confer these findings in 
the context of pulmonary physiology.  A recent study by North et al. demonstrates 
altered pulmonary function with exposure to particulate matter (North et al., 2011).  It 
was shown that in animals challenged with ovalbumin, exposure to ambient air particles 
augments airway resistance and hyperresponsiveness (North et al., 2011).  While 
MWCNTs are known to augment pre-existing allergic conditions, they are also able to 
independently produce adverse pulmonary responses.  However, the effects of 
MWCNTs on pulmonary function have yet to be determined.  
Pulmonary function testing is a valuable tool to evaluate phenotypic 
characteristics of mouse respiratory disease that might be caused by nanoparticle 
exposure.  Hamilton et al. have demonstrated that BALB/c mice exposed to carbon 
nanoparticles had increased airway hyperresponsiveness as measured by changes in 
PenH using barometric whole body plethysmography (Hamilton et al., 2008).  This study 
suggests potential for nanoparticles to influence pulmonary function; however, 
alterations in specific lung function parameters have not been reported.  The FlexiVent 
provides a method to directly measure pulmonary function via the use of 
preprogrammed ventilator and system-specific maneuvers such as forced oscillation 
technique (FOT) (Vanoirbeek et al., 2010).  FOT measures the respiratory impedance 
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(Z) which is considered a detailed measurement of pulmonary mechanics (Glaab et al., 
2007).  FOT is an administration of small pressure oscillations at the airway opening 
using an external generator while simultaneously recording the oscillatory pressure and 
flow signals (Navajas and Farre, 2001; Shalaby et al., 2010).  Respiratory impedance 
(Z) is a complex quantification represented by two components: respiratory resistance 
(Rrs) and reactance (Xrs).  Rrs is derived from airways and lung tissue resistance, 
whereas Xrs is determined by the inertial (I) and elastic (E) properties of the respiratory 
system (Sellares et al., 2009).  This technique provides a means of distinguishing 
central airways from peripheral airways and lung parenchyma.  
In the current study, we tested the hypothesis that instillation of MWCNTs impairs 
pulmonary function in C57BL/6 mice due to development of lung inflammation and 
fibrosis.  As will be shown, mice instilled with MWCNTs exhibited increased 
inflammatory cell infiltration, collagen deposition, and granuloma formation that led to 
deteriorating pulmonary function 30 days following instillation.  Pulmonary exposure of 
MWCNTs induces an inflammatory signature marked by cytokine (IL-33), chemokine 
(Ccl3 and Ccl11), and protease (Mmp13) production which collectively promote 
inflammatory and fibrotic changes within the lung.    
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METHODS 
Animals 
Male C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME, 
USA) at 9 to 10 weeks of age.  The average weight of the C57BL/6 mice was 27.4 ± 
0.58 g.   Mice were randomly assigned to five groups (6-8 mice/group) which included 
naïve, vehicle (10% surfactant in saline), 1 mg/kg, 2 mg/kg, or 4 mg/kg MWCNTs.  Mice 
received a single dose of MWCNTs by oropharyngeal aspiration of 1, 2, or 4 mg/kg 
body weight of MWCNTs or 10% surfactant in saline as vehicle control, following 
administration of isoflurane anesthesia (Wingard et al., 2011). Clinical grade surfactant 
(Infasurf) was kindly provided by ONY company (Amherst, NY, USA).  Pulmonary 
function testing was performed on mice 30 days post-instillation.  Following pulmonary 
function measurements mice were euthanized for bronchoalveolar lavage and collection 
of lung tissue.  All animal procedures were conducted in accordance with the National 
Institutes of Health guidelines and approved by the East Carolina University Institutional 
Animal Care and Use Committee. All animals were treated humanely and with regard 
for alleviation of suffering. 
 
MWCNT Characterization 
Commercial grade multi-walled carbon nanotubes were generously provided by 
NanoTechLabs, Inc (Yadkinville, NC). We performed transmission and scanning 
electron microscopy studies using Hitachi H-9500, S-4800 microscopes to obtain length, 
diameter distribution and elemental composition. Raman spectra were obtained using 
Ar+ ion excitation at 514.5 nm coupled with a Dilor XY triple grating monochromator 
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equipped with thermoelectric cooled CCD. The surface area, pore volume and pore size 
distribution of the MWCNTs were obtained using a physisorption analyzer 
(Micromeritics ASAP 2010) and derived based on the Brunauer-Emmett-Teller (BET) 
equation (Brunauer, 1938) and the Barrett–Joyner–Halenda (BJH) method (Barrett, 
1951). The MWCNTs were dispersed in a saline solution containing 10% surfactant at 2 
μg/μl and the mixture was bath-sonicated (1510R-MTH, Branson Ultrasonics Corp.) for 
45 minutes to obtain a suspension. The hydrodynamic size distribution, a parameter 
describing the effective diameter of a diffusing particle, was characterized using 
dynamic light scattering (Nanosizer S90, Malvern Instruments). The zeta potential and 
isoelectric point (IEP) are primary indicators for describing the surface charge and 
stability of MWCNT suspension, and were determined using a zeta potential device 
(Zeta ZS, Malvern Instruments) with the pH value of the suspension adjusted from 2 to 
7 using HCl. 
 
Thermogravimetric analysis 
The thermogravimetric analysis of our MWCNT was carried out in a Perkin Elmer 
Thermogravimetric Analyzer Pyris 1 TGA. About 40-50 % of the volume of the platinum 
pan was filled with MWCNTs. The sample was then heated from 30°C up to 800°C at a 
heating rate of 20°C/min in an air atmosphere using an air flow rate of 20 ml/min. The 
final goal of this analysis was to determine the ash content of each sample. The 
following thermograms (Figure 2.2) confirm that ~4.8 wt% of catalyst was present in the 
sample. 
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Elemental Analysis 
In order to confirm the catalyst composition, we obtained energy dispersive X-ray 
spectra of our samples on Hitachi S-4800 scanning electron microscope. The results 
reveal a Fe Ka line ~ 6.40 eV confirming the presence of Fe catalyst particles in our 
sample (See Figure 2.3).  
 
Pulmonary Function Testing 
Thirty days following instillation of MWCNTs, all mice were anesthetized, 
tracheostomized, and placed on the FlexiVent system (SCIREQ, Montreal, QC, 
Canada) for forced oscillatory measurements. Mice were anesthetized with 
tribromoethanol (TBE) (400 mg/kg) and paralyzed with pancuronium bromide (1 mg/kg) 
to prevent spontaneous breathing. Mice were ventilated with a tidal volume of 10 mL/kg 
at a frequency of 150 breaths/min and a positive end expiratory pressure of 3 cm H2O to 
prevent alveolar collapse.  Total lung capacity (TLC), Snapshot, Quickprime-3, and 
pressure-volume (PV) loops with constant increasing pressure (PVr-P) were 
consecutively performed using the Flexivent system. A TLC perturbation maximally 
inflates the lungs to a standard pressure of 30 cm H2O followed by a breath hold of 
typically a few seconds to establish a consistent volume history.  A snapshot 
perturbation maneuver uses a three-cycle sinusoidal wave of inspiration and expiration 
to measure total respiratory system resistance (R), dynamic compliance (C), and 
elastance (E). A Quickprime-3 perturbation, which produced a broadband frequency 
(0.5 to 19.75 Hz) over 3 seconds, measures Newtonian resistance which is a measure 
of central airway resistance (Rn), inertance (I), tissue damping (G), tissue elastance (H) 
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and hysteresivity (eta).  PV loops were generated between 30 cm H2O to -30 cm H2O 
pressure to obtain vital capacity (A), the upper portion of the deflation PV curve (K), 
quasi-static compliance (Cst) and elastance (Est), and the area of PV loop (Area).  All 
perturbations were performed until three acceptable measurements with coefficient of 
determination (COD) ≥ 0.9 were recorded in each individual subject. 
 
BAL and Cell Differential Counts  
After measuring pulmonary function parameters, the right lung of each mouse 
was lavaged in situ four times with a specific volume (26.25 mL/kg body weight) of ice-
cold Hanks balanced salt solution (HBSS).  The first aliquot of bronchoalveolar lavage 
fluid (BALF) was collected separately for cytokine analysis, while aliquots 2-4 were 
pooled. All BALF was centrifuged at 1000 g for 10 min at 4oC. Total cells from all 
lavages were pooled and counted and 20,000 cells were centrifuged using a Cytospin 
IV (Shandon Scientific Ltd., Cheshire, UK) and stained with a three-step hematology 
stain (Richard Allan Scientific, Kalamazoo, MI, USA). Cell differential counts were 
determined by morphology with evaluation of 300 cells per slide. 
 
Lung Histopathology 
Unlavaged left lungs from C57BL/6 mice in each treatment group were inflated 
with 10% neutral buffered formalin fixative for 24-72 hrs.  Lung tissue was then cut, 
processed, and embedded in paraffin, and 5 µM sections were mounted on slides.  
Sections were stained with hematoxylin and eosin (H&E) or Masson’s trichrome stain to 
detect inflammatory, morphological changes and collagen deposition. 
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Sircol Collagen Assay 
Soluble collagen content within total lung was determined using the Sircol 
Collagen Assay (Biocolor, Belfast, UK).  Lavaged right lung was collected and 
homogenized in 2 mL of RIPA buffer including protease inhibitors.  Supernatants were 
collected from each sample after centrifugation at 10,000 g for 10 minutes at 4°C.  
Sircol dye reagent (1 mL) was added to 50 µL of each sample or varying concentrations 
of collagen standard to generate a calibration curve.  Following a 30 min incubation 
period, samples were centrifuged at 10,000 g for 10 minutes.  The collagen-dye 
precipitate was reconstituted in 1 mL of alkali reagent and absorbance was read at 540 
nm and total collagen content was calculated from the standard curve. 
 
Mouse Fibrosis PCR-Array 
Total RNA from left lung tissue of additional mice was isolated using a Qiagen 
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s 
recommendations. Total RNA (2.5 g) was reverse-transcribed to cDNA using 
SABiosciences’s RT2 First Strand Kit (Qiagen, Frederick, MD, USA) and applied to 
Mouse Fibrosis PCR Arrays (Cat.# PAMM-120; 96-well format) following SABiosciences 
recommendations. Real-time PCR were performed in an Applied Biosystems 
StepOnePlus Real-Time PCR System (ABI, Foster City, CA, USA). Data were 
interpreted using SABiosciences’ web-based PCR array analysis tool. 
 
qPCR 
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Total lung RNA was reverse transcribed using a QuantiTect reverse transcription 
kit (Qiagen). Quantitative real-time PCR was performed using QuantiTect primer assays 
and SYBR green master mix to verify expression of Ccl3, Ccl11, Mmp13, and IL-33 
found in the mouse fibrosis PCR-array.  An Applied Biosystems StepOnePlus Real-
Time PCR System (ABI) was used to obtain cycle threshold (Ct) values for target and 
internal reference cDNA levels. Target cDNA levels were normalized to GAPDH, an 
internal reference, using the equation 2-[ΔCt], where ΔCt is defined as Cttarget- Ctinternal 
reference.  Values shown are the average of six independent experiments. 
 
ELISA and MMP13 Activity Assays 
Chemokine (CCL3 and CCL11) and cytokine (IL-33) levels were quantified in 
BALF using DuoSet ELISA kits (R&D Systems, Minneapolis, MN) in accordance with 
the manufacturer’s instructions.  MMP13 activity assays were performed using 
SensoLyte® MMP-13 Assay Kit (AnaSpec, San Jose, CA). BALF (50 µL) containing 
MMP13 was activated with 1 mM 4-aminophenylmercuric acetate (APMA) and the 
assay was performed according to the manufacturer’s recommendations. Fluorescence, 
resulting from enzyme-mediated conversion of the fluorogenic substrates, was 
immediately measured by a Synergy™ HT Multi-Detection Microplate Reader (BioTek, 
Winooski, VT) using black, round-bottom 96-well plates (Corning, Corning, NY) and 
continuously recording data every 5 min for 60 min. The relative fluorescence unit 
(RFU) was calculated by subtracting fluorescence in the substrate control well from all 
experimental wells. The MMP13 activity of test samples was calculated as the initial 
reaction velocity (Vo) in RFU/min. 
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Statistical Analyses 
All data are presented as means ± SEM and were analyzed by one-way ANOVA, 
with differences between groups assessed using Bonferroni post hoc tests. Graphs and 
analysis were performed using GraphPad Prism 5 software (GraphPad, San Diego, 
CA). Differences were considered statistically significant at p < 0.05. 
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RESULTS 
MWCNT Characterization 
Our electron microscopy studies revealed that the MWCNTs used in this study 
were several microns long with a bi-modal diameter distribution exhibiting peaks at 
~12.5 and 25 nm (Figures 2.1A, 2.1B & 2.1C).  In MWCNT Raman spectra, the 
presence of strong disorder band ~1350 cm-1 indicates the defective nature of the 
nanotubes.  Specifically, the ratio (R=ID/IG) between the intensity of disorder band (D-
band) and graphite-like band (G-band) was found to be 0.65 (Figure 2.1D).  The 
elemental analysis indicated presence of Fe catalyst in MWCNT samples (Figure 2.2 & 
2.3).  Further, the TGA studies showed that the MWCNT samples possess ~ 5 wt% of 
Fe catalyst (Figure 2.2 & 2.3).  The surface area of the MWCNTs was determined to be 
113.103 m2/g, based on the BET equation.  The pore volume of the MWCNTs, defined 
as the ratio of the MWCNTs’ air volume to their total volume, was determined to be 
0.688 cm³/g utilizing the BJH method.  The hydrodynamic sizes of the MWCNT 
suspension displayed two peaks, a major one at 200 ± 50 nm and another at 1,000 ± 
150 nm (Figure 2.4A).  The larger sized peak was caused by the bundling of the 
nanotubes through hydrophobic interaction and pi-stacking.  The MWCNT suspension 
displayed a zeta potential of -44.6 mV, suggesting a very stable colloidal state of the 
nanomaterial.   
 
MWCNTs Induce Pulmonary Inflammation and Granuloma Formation in C57BL/6 
Mice 
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To investigate the inflammatory effects of MWCNT exposure that may be 
associated with function changes, C57BL/6 mice treated with 10% saline/surfactant or 
increasing doses of MWCNTs underwent bronchoalveolar lavage (BAL) 30 days post-
exposure.  Differential cell counts obtained from BAL demonstrated persistent 
inflammation with pulmonary infiltration of multiple cell types (Table 2.1).  Statistically 
significant elevations in macrophage, epithelial cell, and neutrophil numbers were 
observed in animals exposed to the highest dose MWCNT (4 mg/kg), along with an 
overall increase in total cell recruitment (p<0.001).  Exposure to both the 1 and 2 mg/kg 
MWCNT treatments displayed significant increases in epithelial and neutrophil cell 
counts (p<0.05) compared to mice treated with vehicle.  Increases in eosinophil 
numbers were observed with MWCNT exposure, but did not reach significance 
compared to control mice.  Histological evaluation of lung sections confirmed the altered 
inflammatory cell profile and additionally revealed increased collagen deposition as well 
as changes in lung morphology following MWCNT aspiration.  Quantification of collagen 
content within lung tissue demonstrated a significant increase in MWCNT (4 mg/kg) 
exposed mice compared to naïve mice (Figure 2.5).  However, no statistically significant 
difference was found between vehicle and MWCNT treated mice, nor was there a 
statistical difference between naïve and vehicle treated mice. Oro-pharyngeal aspiration 
of MWCNTs resulted in wide distribution of granulomatous foci containing MWCNT 
agglomerates and MWCNT laden macrophages throughout the lung parenchyma 
(Figure 2.6B) as well as peribronchiolar and perivascular regions (Figure 2.6B, 2.6D & 
2.6F).  In contrast, mice exposed to vehicle control did not display any inflammation or 
granulomas (Figure 2.6A, 2.6C, & 2.6E). 
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Instillation of MWCNTs in C57BL/6 Mice Elicits Dose-Dependent Changes in 
Pulmonary Function  
To determine if MWCNT exposure elicits any physiologically relevant toxicity, we 
examined pulmonary function in C57BL/6 mice following instillation of vehicle, 1, 2, or 4 
mg/kg of MWCNTs.  As shown in Figure 2.7, the snapshot perturbation (Figure 2.7A, 
2.7B & 2.7C) in C57BL/6 mice revealed a dose-dependent pulmonary response to 
MWCNT instillation with a statistically significant increase in R compared to vehicle 
treated and naïve mice (Figure 2.7A).  Further, MWCNT instillation led to a statistically 
significant decrease in C as compared to the naïve mice, but this did not reach 
significance as compared to vehicle treated mice (Figure 2.7C).  The quick-prime 3 
perturbation (Figure 2.7D, 2.7E & 2.7F) further demonstrated a moderate dose 
dependent pulmonary response to MWCNTs with increases in Rn, G, and eta following 
pulmonary instillation of 1, 2, or 4 mg/kg MWCNTs.  Mice treated with 4 mg/kg 
MWCNTs displayed significant increases in tissue damping (G) (Figure 2.7E) and 
hysteresivity (eta) (Figure 2.7F) compared to both the naïve and vehicle groups.  
Meanwhile, both G and eta displayed a significant dose dependent response to 
MWCNTs.  
The PVr-P loop perturbations showed dose-dependent decreases in the deflating 
PV loop (K) (Figure 2.8B) and static compliance (Cst) (Figure 2.8C).  Both reductions of 
K and Cst were statistically significant in the 4 mg/kg treated group compared to naïve 
mice; however, the change in Cst was not statistically different from vehicle control.  As 
expected, Est showed the opposite trend as Cst, but differences between treatment 
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groups were not statistically significant.  In contrast, the area between the limbs of the 
PV loop displayed a statistically significant increase in the 4 mg/kg treated mice 
compared to the vehicle group (Figure 2.8E), but was not statistically different from 
naïve or other MWCNT treated mice.  No statistically significant differences were found 
between naïve and vehicle treated mice in Figure 2.7 and Figure 2.8. 
 
Ccl3, Ccl11, Mmp13 and IL-33 are Increased in the Lungs and BALF of C57BL/6 
Mice instilled with MWCNTs 
To assess potential mechanisms involved in MWCNT directed pulmonary 
inflammation, fibrosis and alteration of lung function, we employed a mouse fibrosis 
PCR array to investigate the expression of 84 keys genes associated with fibrosis.  
Gene expression was analyzed using unlavaged lung tissue homogenates from mice 
exposed to vehicle or 4 mg/kg MWCNT.  Messenger RNA levels of multiple fibrotic 
mediators that were up- or down-regulated > 2 fold in MWCNT instilled mice are shown 
in Table 2.2.  To verify PCR array data on dose dependent changes in gene expression 
induced by MWCNT exposure, mRNA levels of Ccl3, Ccl11, and Mmp13 were analyzed 
in vehicle, 1, 2, and 4 mg/kg MWCNT instilled mice.  As shown in Figure 2.9, mRNA 
levels of Ccl3, Ccl11, and Mmp13 were increased in all MWCNT-treated groups with a 
statistically significant increase observed in the 2 mg/kg MWCNT group compared to 
vehicle control. 
In addition to mRNA levels of Ccl3, Ccl11, and Mmp13; we assessed protein 
levels of chemokines, Ccl3 (Mip1 ) and Ccl11 (eotaxin), and activity levels of Mmp13 in 
BALF of vehicle and MWCNT instilled mice.  Similar to mRNA levels, both Ccl3 and 
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Ccl11 levels were elevated in MWCNT instilled mice but did not reach significant levels 
when compared to vehicle treated mice (Figures 2.10A & 2.10B).  Thirty days post-
MWCNT instillation, we observed dose-dependent increases in Mmp13 levels as well as 
collagenase activity in BALF from MWCNT instilled mice with statistically significant 
increases in the 4 mg/kg MWCNT instilled mice compared to vehicle control (Figures 
2.10C & 2.10D). 
In addition to mRNA levels of Ccl3, Ccl11, and Mmp13; we assessed protein 
levels of chemokines, Ccl3 (Mip1 ) and Ccl11 (eotaxin), and activity levels of Mmp13 in 
BALF of vehicle and MWCNT instilled mice.  Similar to mRNA levels, both Ccl3 and 
Ccl11 levels were elevated in MWCNT instilled mice but did not reach significant levels 
when compared to vehicle treated mice (Figures 2.10A & 2.10B).  Thirty days post-
MWCNT instillation, we observed dose-dependent increases in Mmp13 levels as well as 
collagenase activity in BALF from MWCNT instilled mice with statistically significant 
increases in the 4 mg/kg MWCNT instilled mice compared to vehicle control (Figures 
2.10C & 2.10D). 
To further investigate mechanisms involved in the inflammatory response, we 
identified IL-33, a novel alarmin and Th2 cytokine, as a potential mediator in MWCNT 
induced pulmonary inflammation.  While no dose dependent change was evident, gene 
expression analysis of lung tissue from mice 30 days post-exposure to 1, 2, or 4 mg/kg 
MWCNTs demonstrated a statistically significant >2-fold induction in Il-33 (Figure 
2.11A).  Similarly, assessment of IL-33 protein expression in BALF exhibited a 
statistically significant increase for all dose groups compared to the vehicle control 
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(Figure 2.11B).  There were no significant differences in Il-33 gene expression or protein 
levels between MWCNT dose groups. 
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Table 2.1 Effect of MWCNT instillation on pulmonary cell populations in C57BL/6 
mice 
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Figure 2.1 Characterization of MWCNT in Dry Powder Form 
 
Characterization of multi-walled carbon nanotubes was determined using electron 
microscopy and Raman spectroscopy.  (A & C) The diameter of the MWNCTs was 
determined by measuring individual nanotubes visualized by TEM.  (B) This SEM image 
shows a bundle of MWCNTs, with individual nanotubes indicated by arrows.  The length 
of individual nanotubes was determined to be several m long using SEM. (D) The 
Raman spectrum of MWCNT obtained using 514.5 nm laser excitation.  The presence 
of strong disorder band (ID/IG peak ratio) suggests the existence of structural defects as 
determined by Raman spectroscopy. 
  
57 
 
 
 
  
58 
 
Figure 2.2 Thermogravimetric analysis 
 
The thermogram for MWCNT used in this study reveals that the catalyst amounts to 
~4.8 wt% of the sample 
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Figure 2.3 Elemental Analysis of MWCNT 
 
The top panel shows the region of the sample used for obtaining the energy dispersive 
X-ray spectra. The bottom panel shows the presence of C or carbon (from MWCNTs 
and the SEM tape) along with the presence of Fe catalyst. 
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Figure 2.4 Characterization of MWCNT in Suspension 
 
The size and charge characteristics of the MWCNTs were determined in a suspension 
of 10% surfactant saline.  (A) The size of MWCNT bundles in suspension was 
determined by dynamic light scattering.  (B) The zeta potential and isoelectric point 
(indicated by the arrow) were determined for the MWCNTs suspended in 10% 
surfactant saline solution.  
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Figure 2.5 Increased collagen content in lung tissue of MWCNT exposed C57BL/6 
mice 
 
Collagen content was determined by lung tissue harvested from mice 30 days post-
exposure to vehicle control (10% surfactant in saline) or MWCNTs (1, 2, or 4 mg/kg).  
Mice exposed to the high dose MWCNT (4 mg/kg) displayed significant increase in 
collagen levels compared to naïve mice.  All values are expressed as mean ± SEM 
(n=6-11). *p < 0.05 compared to naïve mice and + p < 0.05 compared between two 
groups.  No significant differences were found between naïve and vehicle treated 
groups.  In addition, differences between vehicle and treatment groups were not 
significant. 
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Figure 2.6 Histopathology of lungs exposed to MWCNT displays granulomatous 
and fibrotic tissue at 30 days post-exposure 
 
Mice instilled with (A) 10% saline in surfactant vehicle control display normal lung 
morphology while mice instilled with (B) 4mg/kg MWCNTs exhibit widely dispersed 
deposition of MWCNT aggregates within lung tissue.  Masson’s trichrome staining 
shows collagen rich granulomas and surrounding fibrotic tissue (blue) in lungs of mice 
exposed to (D) MWCNTs, but not (C) vehicle control.  H&E staining demonstrates 
granulomatous peribronchiolar foci in lungs of mice exposed to MWCNT (F) but not 
vehicle (E).  Agglomerates of MWCNT within granulomas are indicated by arrows.  
Images are representative of 4 mice per group with original magnifications of 25x (A-B), 
200x (C-D) and 400x (E-F). 
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Figure 2.7 Impaired pulmonary function as determined by Snapshot and Quick-
prime 3 perturbation after MWCNT instillation 
 
The Snapshot and Quick-prime3 perturbations were performed in tracheotomized 
C57BL/6 mice instilled with increasing doses of MWCNTs.  Since Snapshot perturbation 
measures the lung as a single compartment, the parameters, R (A), E (B), and C (C), 
are indicative of the whole respiratory system including lung and chest wall. On the 
other hand, Quick-prime 3 perturbation measures the lung as multiple compartments. 
The parameters can differentiate between central airway (Rn (D)) and peripheral lung 
tissue (G (E) and eta (F)). The mean ± SEM of six mice per group are shown, *p < 0.05 
and ** p < 0.01 compared with the naïve mice, # p < 0.05 and ## p < 0.01 compared with 
the vehicle control (10% surfactant in saline) mice; + p < 0.05, ++ p < 0.01, and +++ p < 
0.001 compared between two groups. No statistically significant differences were found 
between naïve and vehicle treated mice. 
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Figure 2.8 Impaired pulmonary function as determined by PVr-P perturbation after 
MWCNT instillation 
 
The PVr-P perturbation was performed in tracheotomized C57BL/6 mice instilled with 
vehicle (10% surfactant in saline) or increasing doses of MWCNTs. From PV loops, 
perturbation parameters, (A) A, (B) K, (C) Cst, (D) Est, and (E) Area were determined. 
The mean ± SEM of six mice per group are shown, *p < 0.05 and ** p < 0.01 compared 
with the naïve mice; # p < 0.05, ## p < 0.01, and ### p < 0.001 compared with the vehicle 
control mice; ++ p < 0.01 compared between two groups. No statistically significant 
differences were found between naïve and vehicle treated mice. 
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Table 2.2 Lung pro-fibrotic gene expression in MWCNT instilled C57BL/6 mice 
compared to vehicle control  
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Gene Description p-Value Fold Change 
Mmp13 Matrix metallopeptidase 13 0.0253 7.92 
Ccl3 Chemokine (C-C motif) ligand 3 0.0078 3.10 
Ccl11 Chemokine (C-C motif) ligand 11 0.0038 2.76 
Plau Plasminogen activator, urokinase 0.0461 2.11 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 0.0243 -2.05 
Jun Jun oncogene 0.0366 -2.09 
Eng Endoglin 0.0007 -2.19 
Fasl Fas ligand (TNF superfamily, member 6) 0.0044 -2.20 
Smad6 MAD homolog 6 (Drosophila) 0.0004 -2.40 
Plg Plasminogen 0.0290 -2.44 
Serpina1a Serine (or cysteine) peptidase inhibitor, clade A, member 1a 0.0312 -2.46 
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Figure 2.9 Induction of Ccl3, Ccl11, and Mmp13 in lungs of C57BL/6 mice exposed 
to MWCNTs 
 
Real-Time PCR analysis was performed in the left lung of vehicle (10% surfactant in 
saline), 1 mg/kg, 2 mg/kg, and 4 mg/kg MWCNTs instilled C57BL/6 mice for genes (A) 
Ccl3, (B) Ccl11, and (C) Mmp13. The mean ± SEM of six mice per group are shown, # p 
< 0.05, ## p < 0.01, and ### p < 0.001 compared with the vehicle control mice; + p < 0.05 
compared between two groups.  
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Figure 2.10 Increased Ccl3, Ccl11, and activity of Mmp13 in BAL fluid after 
instillation with MWCNTs 
 
ELISA analysis was performed in the BAL fluid of vehicle, 1 mg/kg, 2 mg/kg, and 4 
mg/kg MWCNT instilled C57BL/6 mice for chemokines (A) Ccl3 and (B) Ccl11. 
Collagenase activity in the BAL fluid of vehicle control (10% surfactant in saline) and 
MWCNT instilled mice was measured using SensoLyte® Mmp13 Assay Kit. (C) The 
relative fluorescence units (RFUs) and (D) the reaction velocity of Mmp13 were dose-
dependent increased 30 days post-MWCNT instillation. The mean ± SEM of six mice 
per group are shown, # p < 0.05 and ## p < 0.01 compared with the vehicle control mice. 
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Figure 2.11 Induction of IL-33 gene and protein expression in C57BL/6 lung tissue 
and BALF 30 days post-exposure to MWCNTs 
 
Gene expression of IL-33 (A), determined by Real-Time PCR, demonstrated an 
approximate three-fold increase in left lung tissue of mice instilled with MWCNTs 
compared to vehicle control mice.  Correspondingly, ELISA protein analysis (B) of IL-33 
in BALF of mice exposed to MWCNTs was also significantly increased at all doses (1, 2, 
and 4 mg/kg) compared to vehicle control (10% surfactant in saline).  All values are 
expressed as mean ± SEM (n=6-11). #p < 0.05 compared to vehicle control mice and ### 
p < 0.001 compared with the vehicle control mice. 
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DISCUSSION 
Pulmonary toxicity of MWCNTs has been reported in both mouse and rat models 
(Han et al., 2010; Muller et al., 2005; Reddy et al., 2012).  Instillation of MWCNT into the 
lungs of mice and rats has been shown to induce fibrosis (Mitchell et al., 2007); 
however, extensive evaluation of pulmonary function changes in animals instilled with 
MWCNTs has not been reported.  In this study, we demonstrated that 30 days following 
MWCNT instillation, C57BL/6 mice exhibited changes in pulmonary function that were 
consistent with pulmonary inflammation, increased collagen deposition and granuloma 
formation.  Additionally, increased levels of Ccl3, Ccl11, and Mmp13 were observed in 
C57BL/6 mice instilled with different doses of MWCNTs.  Taken together, these results 
suggest that MWCNT exposure could lead to impaired pulmonary function due to 
inflammatory and fibrotic remodeling of lung tissue.   
Due to the implication that MWCNTs may adversely affect human health and 
safety, appropriate dosing of animals was essential to evaluate the pertinence of these 
findings in regard to human exposure levels.  Studies conducted in industrial plants 
indicated nanoparticle exposure levels up to 0.5 mg/m3 for an 8-hour work day and 40-
hour work week (Demou et al., 2008).  Additional evaluations of carbon nanotubes in 
manufacturing and research facilities, found airborne levels during handling to be as low 
as 53 µg/m3 (Maynard et al., 2004) and as high as 400 µg/m3 (Han et al., 2010; Porter 
et al., 2010).  Shvedova et al., report that human occupational exposure levels of 5 
mg/m3 over the course of an 8-hour day and 40-hour work week equate to 
approximately 20 µg of MWCNT aspiration in a mouse model (Shvedova et al., 2005).  
Current proposed guidelines by the National Institute for Occupational Safety and 
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Health (NIOSH) limits exposure to 7 µg/m3, the lowest detectable level of airborne CNT 
using the latest analytical methods (2010).  The doses used in this study, 1, 2 and 4 
mg/kg MWCNTs (equivalent to 27, 54, and 108 µg of MWCNT in the average 27 g 
mouse used in this study), were selected based on these limited exposure studies and 
doses previously reported in the literature for rodent studies (Porter et al., 2010).  
Furthermore, the MWCNTs were dispersed in 10% surfactant in saline, a physiologically 
relevant medium, shown to effectively reduce aggregation of nanotubes in solution 
(Wang et al., 2011b).  Data from this study demonstrated a persistent inflammatory 
response and the development of granulomatous and collagen-rich fibrotic tissue in 
C57BL/6 mice, similar to previously reported findings (Porter et al., 2010; Ryman-
Rasmussen et al., 2009b).  Post-exposure to MWCNTs at 90 days exhibited 
granulomatous foci similar to those found in chronic human granulomatous disorders 
(Huizar et al., 2011).  In fact, due to their ability to produce a robust granulomatous 
response, the use of MWCNTs has been proposed as a novel murine model to study 
chronic granulomatous disease (Huizar et al., 2011).  In the present study, we 
demonstrated that focal aggregates of MWCNTs were present at the core of the 
granulomas and surrounding fibrotic tissue (Fig 2.6D).  In addition, our data indicated 
that intact MWCNTs do not congregate to form airway granulomas, but are dispersed 
throughout the lung tissue (Fig 2.6B) contrary to reports from previous investigators 
(Muller et al., 2005).  Furthermore, studies have shown that MWCNTs are not only 
found in the periphery of the lungs post-exposure, but have also been found to 
translocate to the pleural space (Ryman-Rasmussen et al., 2009b).  Data from this 
study are consistent with previous reports that MWCNTs induce pulmonary 
  
82 
 
inflammation and fibrosis, and are widely distributed through the lung following 
exposure.  Further, we have now shown that these severe adverse pulmonary 
responses have a negative impact on pulmonary function.    
In this study, pulmonary functional variables were evaluated in C57BL/6 mice 
exposed to different doses of MWCNTs using the FlexiVent system.  The Snapshot 
perturbation was imposed to measure resistance (R), dynamic compliance (C), and 
elastance (E) of the whole respiratory system (including airways, lung, and chest wall).  
Our data showed that R was significantly increased at the highest dose of MWCNT with 
a concomitant declined in dynamic compliance (C).  The decrease in C is consistent 
with findings in a bleomycin-induced model of pulmonary fibrosis in mice (Vanoirbeek et 
al., 2010).  However, that study did not demonstrate an increase in R.  This discrepancy 
is likely due to the fact that inflammation was attenuated by use of cyclophosphamide.  
Thus, in our study, the consistent elevation in numbers of inflammatory cells may have 
contributed to the increased R observed.  Because R reflects the combined resistance 
contributed by both the airways and lung parenchyma, we employed the constant-phase 
model to distinguish between central and peripheral respiratory mechanics and to 
provide information about the heterogeneity of the respiratory response (Shalaby et al., 
2010). 
Tissue damping (G), which reflects parenchymal distortion, showed a dose-
dependent increase in MWCNT instilled mice which was likely due to inflammatory 
infiltrates, as well as granuloma formation in the peribronchiolar and alveolar regions of 
the lung.  Since these structures account for a major portion of the cross-sectional area 
of the lung, any obstruction in the distal airways and/or alveolar spaces could contribute 
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to an increase in R.  Furthermore, the decrease in C may suggest that the alveoli are 
not fully expanding as a result of alveolar volume reduction which is likely due to 
inflammation and/or granuloma formation.  This would reduce the traction normally 
exerted on the conducting airways at high lung volume and thereby also contribute to 
changes in resistance (R).  Similar to Rn, H, a measure of tissue elastance, also 
displayed a non-significant trend towards increased elastance with increasing doses of 
MWCNT (data not shown).  Tissue elastance is typically elevated with fibrotic lung 
disease; but the patchy nature of the granulomatous/fibrotic lesions seen in this model 
may account for the lack of significance.  However, eta (G/H) was dose-dependently 
increased with MWCNT instillation and was significantly elevated at the highest dose, 
indicating heterogeneity in the combined inflammatory and fibrotic responses to 
MWCNTs.  On the other hand, Rn showed a trend toward dose-dependent increases 
that did not reach significance, suggesting that MWCNTs may have a minor effect on 
central airways.  In support of this, we observed only minor inflammation within the 
central airways.  However, this effect, while small with MWCNTs alone, may explain 
enhancement of airway responses to methacholine in models of allergic airway disease 
by exposure to air pollution (North et al., 2011) observed in other studies.  Along the 
same line, our study showed a MWCNT-induced increase in eosinophil numbers and 
eotaxin levels (Ccl11) which may also contribute to MWCNT enhancement of allergic 
airway disease. 
Static compliance (Cst) and the upper portion of the deflation PV curve (K), 
parameters derived from PVr-P maneuvers, declined significantly at the highest dose of 
MWCNTs which is typical of fibrotic lung disease. In contrast to our findings, Kamata et 
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al. (Kamata et al., 2011) reported that carbon black nanoparticles had no effect on lung 
compliance.  This might be due to the physicochemical differences between carbon 
black nanoparticles and MWCNTs.  A decrease in Cst was also observed in the vehicle 
treated mice suggesting that the administration of high doses of pulmonary surfactant 
reduces lung compliance.   
Taken together, our pulmonary function findings suggest that MWCNT exposure 
results predominantly in peripheral respiratory disease as a result of combined 
inflammatory infiltrates and granulomatous/fibrotic parenchymal responses, reflected by 
a decline in pulmonary function.  Consistent with other reports, we observed significant 
granuloma formation with fibrotic content which likely contributed to restrictive changes 
in pulmonary function (Huizar et al., 2011).  Translocation and penetration of MWCNTs 
into pleural space, as previously shown, may also contribute to peripheral respiratory 
injury and subsequent structural changes (Mercer et al., 2010; Ryman-Rasmussen et 
al., 2009b).  
To begin examining potential molecular mechanisms by which MWCNT 
instillation mediates impaired pulmonary function, gene and protein expression of 
cytokines and chemokines were examined to identify fibrotic and inflammatory 
responses.  PCR arrays were utilized to identify changes in gene expression related to 
the development of fibrosis.  We identified Mmp13, Ccl3, and Ccl11 as three highly 
upregulated gene products.  Mmps can be divided by structure and substrate specificity 
into several subgroups including collagenases, gelatinases, stromelysins, and 
membrane-type (MT) Mmps (Selman et al., 2000).  Imbalanced expression of MMPs 
has been associated with fibrosis (Kim et al., 2011).  Mmp13, an interstitial collagenase, 
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is considered a key activator in the cascade of proinflammatory reactions leading to 
pulmonary fibrosis (Flechsig et al., 2010).  Furthermore, activation of Mmp13 enhances 
the process of macrophage chemoattraction and infiltration of other inflammatory cells 
following tissue injury.  MWCNT instilled mice exhibited a dose dependent increase in 
Mmp13 production and activity in BAL fluid.  Additionally, Ccl3 (also named MIP-1 ) is a 
critical macrophage chemoattractant in murine wound repair (DiPietro et al., 1998).  In 
our study, increased Ccl3 expression in the lung and Mmp13 activity in BAL fluid 
following MWCNT exposure are likely associated with the collagen deposition and 
granuloma formation in mouse lung exposed to MWCNT.  Lastly, Ccl11, involved in 
eosinophil recruitment, was significantly increased in the lung following MWCNT 
instillation.  This likely contributed to the increasing trend in eosinophils in the BALF 
seen with increasing doses of MWCNT.  Consistent with previous studies (Emad and 
Emad, 2007), an influx of eosinophils into the lungs by a variety of eosinophil 
chemoattractants, such as Ccl11,  was observed.  This classic Th2 driven inflammatory 
response may contribute to the subsequent fibrotic outcome and change in resistance 
that was observed in response to MWCNT exposure.  
Finally, IL-33 was examined for its potential role in inflammatory cell recruitment 
and Th2 immune responses following MWCNT exposure.  IL-33 is a member of the IL-1 
cytokine family and the only known ligand for the ST2 receptor (Schmitz et al., 2005).  
The ST2 receptor is most highly expressed on mast cells and Th2 lymphocytes, and is 
known to exist in at least two isoforms; a transmembrane form and a soluble form which 
is cleaved after activation by IL-33 (Lloyd, 2010).  Haraldsan et al. describe IL-33, as a 
potential alarmin, or immune stimulating danger signal during trauma or infection 
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(Haraldsen et al., 2009; Oppenheim and Yang, 2005).  Studies have confirmed IL-33 as 
a chemoattractant for human and murine Th2 cells (Komai-Koma et al., 2007).  
Furthermore, IL-33 has recently been shown to polarize macrophages to a M2 
phenotype (or alternatively activated macrophages), resulting in enhanced production of 
pro-inflammatory and pro-fibrotic cytokines and chemokines in Th2 driven pathologies 
(Kurowska-Stolarska et al., 2009).  The IL-33/ST2 axis, known to influence these Th2 
cell types including mast cells, macrophages and eosinophils, has been recognized in 
modulating disease pathologies such as anaphylaxis and allergic asthma (Liew et al., 
2010).  A study by Mangan et al. demonstrates that expression of transmembrane ST2 
on Th2 cells negatively impacts both pulmonary physiologic and pathologic responses 
in an OVA-induced pulmonary inflammation mouse model.  Changes in airways 
resistance measures, such as PenH, along with pathologic alterations of pulmonary cell 
infiltrates and cytokine profiles in ST2 knock-out mice indicate a role for IL-33 and ST2 
receptor in regulating allergic inflammatory responses (Mangan et al., 2007).  Further, 
airway hyper-reactivity following allergen challenge can be attenuated by blockade of 
the transmembrane ST2 receptor in BALB/c mice (Kearley et al., 2009).  Thus, during 
injury or insult to the lung, IL-33 upregulation and activation of ST2 receptors may 
significantly impact Th2 driven cell types resulting inflammatory, fibrotic and 
physiological changes.   
Our data show significant increases in IL-33 expression with MWCNT exposure 
compared to vehicle control, demonstrating a potential role in inflammation and fibrosis.  
Mechanistically, the release of chemokines (CCL3 and CCL11), cytokines (IL-33) and 
the activation of MMP13, help to amplify pro-inflammatory and pro-fibrotic mediators, as 
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well as recruit macrophages, neutrophils, and eosinophils into the lung, thereby 
contributing not only to the pathologic inflammatory and fibrotic responses, but also the 
physiologic and functional changes induced by MWCNTs.  
 
CONCLUSION 
In this study, we have demonstrated that MWCNT instillation results in increased 
immune cell infiltration, increased collagen deposition, and a granulomatous response.  
Further, we provide evidence of detrimental lung remodeling exhibited by impaired 
pulmonary function; and begin to identify mechanisms of MWCNT-induced lung 
remodeling through increased expression of CCL3, CCL11, MMP13 and IL-33.  Given 
these data and the increased use of MWCNTs and other nanomaterials, we believe 
further investigation into the toxicity of these materials is warranted.  
CHAPTER 3:  A CARBON NANOTUBE TOXICITY PARADIGM DRIVEN BY MAST 
CELLS AND THE IL-33/ST2 AXIS 
 
PUBLISHED:  Katwa et al. Small 2012, DOI:10.1002/smll.201200873 
 
SUMMARY 
 Concern about the use of nanomaterials has increased significantly in recent 
years due to potentially hazardous impacts on human health.  Mast cells are critical for 
innate and adaptive immune responses, often modulating allergic and pathogenic 
conditions.  Mast cells are well known to act in response to danger signals through a 
variety of receptors and pathways including IL-33 and the IL-1 like receptor ST2. Here, 
we examined the involvement of mast cells and the IL-33/ST2 axis in the pulmonary and 
cardiovascular responses to MWCNT exposure. The toxicological effects of MWCNTs 
were observed only in mice with a sufficient population of mast cells and were not 
observed when mast cells were absent or incapable of responding to IL-33.  Our 
findings establish for the first time that mast cells and the IL-33/ST2 axis orchestrate 
adverse pulmonary and cardiovascular responses to an engineered nanomaterial, 
giving insight into a previously unknown mechanism of toxicity.  This novel mechanism 
of toxicity could be used for assessing the safety of engineered nanomaterials and 
provides a realistic therapeutic target for potential nanoparticle induced toxicities.   
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INTRODUCTION 
Carbon nanotubes (CNTs) have great versatility in physical and chemical 
properties leading to increased use in biomedical and technological applications.  Their 
unique properties, including high electrical and thermal conductance, high-strength to 
weight ratios, and additional novel physico-chemical properties, have led to significantly 
increased use of CNTs over the past decade (Endo et al., 2008a).  Functionalization of 
CNTs with amino acids, peptides and other molecules has been an important factor in 
providing greater stability and lower cellular toxicity compared to non-functionalized or 
pristine CNTs, making them a promising platform for drug delivery, gene delivery and 
other biomedical applications (Bianco et al., 2005; Dumortier et al., 2006; Liu et al., 
2009).  While the novel applications of CNTs are advantageous, there is increased 
concern about their potentially hazardous effects on human health.  Despite limited 
research on direct effects of CNTs on humans, research in animals has demonstrated 
pristine CNT exposure leads to adverse pulmonary and cardiovascular outcomes.  Due 
to their high aspect ratio characteristics, multi-walled carbon nanotubes (MWCNTs), in 
particular, have been compared to asbestos fibers and as a result, have been 
suggested to induce asbestos-like toxicities (Poland et al., 2008).  Inhalation of 
MWCNTs in animal models elicits detrimental pulmonary responses including 
inflammation, granulomatous disease, fibrosis, and altered lung function (Huizar et al., 
2011; Inoue et al., 2009; Ryman-Rasmussen et al., 2009b; Wang et al., 2011a).  In 
addition, MWCNTs exacerbate cardiac ischemia/reperfusion (IR) injury in mice which 
occurs as early as 1 day post-exposure (Urankar, In Submission 2012b).   
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Mast cells are critical for innate and adaptive immune responses, often 
modulating allergic and pathogenic conditions.  Described as key sensors of cell injury, 
mast cells are well known to act in response to danger signals through a variety of 
receptors and pathways including pathogen associated molecular pattern (PAMP) 
receptors, scavenger receptors and the IL-1-like receptor ST2 (Abraham and St John, 
2010; Enoksson et al., 2011).  The ST2 receptor, which can be activated by its ligand 
interleukin-33, is highly expressed on the surface of mast cells and is pivotal in 
response to pathogenic and, as suggested, xenobiotic insult (Moritz et al., 1998).   
IL-33, a novel cytokine that is a member of the IL-1 family, has recently been 
termed an “alarmin” to describe its potential role in alerting the immune system of tissue 
injury or trauma (Moussion et al., 2008).   Alarmins, also known as endogenous danger 
signals, have been shown to activate receptors on immune cells in order to initiate 
inflammatory responses to cell necrosis (Kono and Rock, 2008).  IL-33 can induce the 
release of Th2 pro-inflammatory cytokines, including IL-6 and IL-13 through the ST2 
receptor in a variety of immune cells including mast cells (Enoksson et al., 2011; Ho et 
al., 2007; Moulin et al., 2007).  As an alarmin, IL-33 has a dual role in not only initiating 
immune responses, but modulating them as well.   
Our understanding of mast cells in disease has been elucidated through the use 
of mast cell deficient mice (KitW-sh mice).  Indeed, KitW-sh mice reconstituted with cultured 
bone marrow derived mast cells (BMMCs) have been utilized as a model for 
investigating the role of mast cells in numerous conditions (Grimbaldeston et al., 2005; 
Wolters et al., 2005).  Through the use of this model, our understanding of mast cells 
now includes their importance in host immune responses to bacterial infections, airway 
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reactivity in asthma, as well as toxicity of Gila monster and scorpion venoms as 
examples (Akahoshi et al., 2011; Sutherland et al., 2011; Yu et al., 2006).   
In the current study, we examined the contribution of mast cells and the IL-
33/ST2 axis to multi-walled carbon nanotube (MWCNT) directed pulmonary and 
cardiovascular toxicity.  As will be shown, MWCNT exposure resulted in adverse 
pulmonary and cardiovascular responses in mice with sufficient mast cell populations, 
while these effects were largely absent in mice deficient in mast cells or mice with mast 
cells unable to respond to IL-33.  Our findings establish for the first time that mast cells 
and the IL-33/ST2 axis modulate adverse pulmonary and cardiovascular responses to 
an engineered nanomaterial, giving insight into a previously unknown mechanism of 
toxicity.   
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METHODS 
MWCNT Characterization  
Multi-walled carbon nanotubes were generously provided by NanoTechLabs, Inc 
(Yadkinville, NC). The dry powder form of MWCNTs was characterized using 
transmission and scanning electron microscopy to obtain length, diameter distribution 
and elemental composition. Raman spectra, surface area, pore volume, pore size 
distribution, hydrodynamic size, zeta potential and isoelectric point of the MWCNTs 
were obtained as previously described (Wang et al., 2011a).  A summary of the 
MWCNT characterization is presented in Tables 3.1 & 3.2.   
 
Cell Culture   
Bone marrow derived mast cells (BMMCs) were generated from femoral bone 
marrow of 4 week old female C57BL/6 or ST2-/- mice and grown at 37°C with 5% CO2.  
BMMCs and ST2-/- BMMCs were cultured in RPMI 1640 medium supplemented with 
(10%) FBS, (100µg/mL) streptomycin, (100 U/mL) penicillin, (1 M) sodium pyruvate, 
non-essential amino acids (Sigma-Aldrich, St. Louis, MO), (25 mM) Hepes, (0.0035%) 
2-mercaptoethanol, and (300 µg/mL) recombinant murine IL-3 (Peprotech, Rocky Hill, 
NJ).  FcεRI expression was determined at 4 weeks, at which time >95% of cells were 
mature BMMCs.  In addition, absence of ST2 receptor expression was determined in 
ST2-/- BMMCs by flow cytometry and IL-33 activation studies. Upon reaching maturity, 
cells were used for reconstitution of B6.Cg-kitW-sh mast cell deficient mice or in vitro 
experiments.  C57BL/6 or ST2-/- BMMCs used for in vitro experiments were exposed to 
BALF acquired from C57BL/6 mice 1 day post-exposure to MWCNT.  C57BL/6 or ST2-/- 
  
93 
 
BMMCs were collected for qPCR analysis of IL-6, IL-33 and OPN, following the 2 hour 
BALF incubation period. 
 
Experimental Animals   
C57BL/6J and B6.Cg-kitW-sh mast cell deficient mice were acquired from Jackson 
Laboratories (Bar Harbor, ME, USA) at 4-10 weeks of age.  ST2-/- mice were generously 
provided by Merck, Inc. and breeding colonies were maintained at East Carolina 
University.  In addition, B6.Cg-kitW-sh mice were reconstituted with wild type (C57BL/6) 
or ST2-/- BMMCs.  They were further divided into 2 treatment groups (6-8 mice/group): 
vehicle (10% surfactant in saline) or (4 mg/kg) MWCNTs.  C57BL/6J, B6.Cg-kitW-sh 
(without reconstitution) and ST2-/- mice were also assigned to the same treatment 
groups.  The dose was determined based on previously published MWCNT dose 
response data (Wang et al., 2011a).  Mice were lightly anesthetized with isofluorane 
and received a single dose of MWCNTs (4 mg/kg body weight) or vehicle (10% 
surfactant) by oropharyngeal aspiration (Wang et al., 2011b).  Clinical grade pulmonary 
surfactant (Infasurf ) was kindly provided by ONY, Inc (Amherst, NY, USA).  Mice were 
sacrificed at 1 or 30 days post-exposure.  Animal protocols and procedures were 
conducted in accordance with the National Institutes of Health guidelines and approved 
by the East Carolina University Institutional Animal Care and Use Committee.  
 
Mast Cell Reconstitution of B6.Cg-kitW-sh Mast Cell Deficient Mice  
C57BL/6J and ST2-/- BMMCs were centrifuged at 1200 rpm for 5 min and 
resuspended in sterile saline.  Wild type (C57BL/6J) or ST2-/- BMMCs (5 x 106 cells in 
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200 µL of sterile saline) were intravenously injected into 4 week old B6.Cg-kitW-sh mice.  
BMMCs were allowed to reconstitute for 8 weeks at which time reconstituted B6.Cg-kitW-
sh mice were instilled with vehicle or MWCNT and sacrificed 1 or 30 days post-exposure 
for pulmonary and cardiovascular endpoints.   
 
Pulmonary Function Testing  
Elastance (E), compliance (C), and Newtonian resistance (Rn) were measured 
by forced oscillatory technique using the FlexiVent system (SCIREQ, Montreal, QC, 
Canada.(Wang et al., 2011a)  Briefly, 30 days following instillation of MWCNTs, mice 
were anesthetized with tribromoethanol (TBE) (400 mg/kg), tracheostomized, and 
placed on the FlexiVent system.  Mice were ventilated with a tidal volume of 10 mL/kg at 
a frequency of 150 breaths/min and a positive end expiratory pressure of 3 cm H2O to 
prevent alveolar collapse. In addition, mice were paralyzed with pancuronium bromide 
(1 mg/kg) to prevent spontaneous breathing.  EKG was monitored for all mice to 
determine anesthetic depth and potential complications that could have arisen during 
testing. Total lung capacity (TLC), Snapshot, Quickprime-3, and pressure-volume (PV) 
loops with constant increasing pressure (PVr-P) were consecutively performed using 
the Flexivent system. All perturbations were executed until three acceptable 
measurements with coefficient of determination (COD) ≥ 0.9 were recorded in each 
individual subject.  
 
BAL and Differential Cell Counts   
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Following pulmonary function testing, mice underwent in situ bronchoalveolar 
lavage (BAL).   The right lung was lavaged four times (26.25 mL/kg body weight) with 
ice-cold Hanks balanced salt solution (HBSS).  Bronchoalveolar lavage fluid (BALF) 
was collected separately for the first lavage and pooled for the remaining 3 lavages.  
BALF samples were then centrifuged at 1000 g for 10 min at 4oC and supernatant from 
the first lavage was snap frozen for cytokine analysis, while cell pellets from all lavage 
samples were combined and counted, followed by resuspension in (1 mL) HBSS.  In 
order to obtain differential cell counts, 20,000 cells from each BALF sample were 
centrifuged using a Cytospin IV (Shandon Scientific Ltd., Cheshire, UK) and stained 
with a three-step hematology stain (Richard Allan Scientific, Kalamazoo, MI, USA). Cell 
differential counts were determined by morphology with evaluation of 300 cells per slide.  
 
Lung Histopathology  
Left lungs from mice were perfused with 10% neutral buffered formalin fixative 
and stored for 24 hrs, then processed and embedded in paraffin.  Samples were then 
sectioned at a thickness of 5 µM and were mounted on slides for staining with 
hematoxylin and eosin (H&E) or Masson’s trichrome stain to detect morphological 
changes and collagen deposition.  MWCNT aggregates localized within the tissue 
sections were confirmed by Raman spectroscopy.(Wang et al., 2011a) 
 
Immunofluorescence  
Unstained histological lung sections from C57BL/6 mice were used for 
immunofluorescence detection of IL-33.  Sections were deparrafinized and 
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subsequently underwent microwave irradiation in citrate buffer for antigen retrieval.  
Sections were then blocked in (5%) filtered fetal bovine serum in Tris buffer saline 
(TBS) with (0.2%) Tween and sodium azide for 2 hours, following which IL-33 primary 
antibody was applied at 1:100 (Novus Biologicals, Littleton, CO) for 48 hours at 4°C.  
Sections were washed 3 times with TBS and incubated in a PE (R-phycoerythrin) 
conjugated secondary antibody at 1:100 (Fitzgerald Industries International, Concord, 
MA) for 2 hours at room temperature.  Following additional washes in TBS with (0.1%) 
Triton X, sections were coverslipped using Prolong gold anti-fade containing a DAPI 
stain (Molecular Probes, Eugene, OR).  Dry sections were imaged using DAPI and 
TRITC filters for nuclear and IL-33 specific staining. 
 
Sircol Collagen Assay   
Sircol Collagen Assay (Biocolor, Belfast, UK) was used to detect soluble collagen 
content within the lung homogenate.  Lavaged right lung was homogenized in 2 mL of 
RIPA buffer containing protease inhibitors and the protocol was conducted according to 
manufacturer’s specifications.  In addition, a BCA protein quantification analysis was 
used to determine total protein content for each sample, of which 100 µg of protein used 
for collagen quantification. 
 
Myocardial Ischemia/Reperfusion (I/R) Injury  
At 1 day post-instillation of MWCNT, mice were anesthetized i.p. 
(intraperitoneally) with 0.005 mL/gram body weight of Ketamine/Xylazine mix (18:2 
mg/mL) to measure ischemia/reperfusion injury in accordance with an established 
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protocol (Weir et al., 2010).  In short, following a midline tracheostomy, mice were 
intubated and ventilated with (100%) oxygen at 115 strokes/min and tidal volume of 
0.25 mL, using a Harvard Inspira Ventilator (Harvard Apparatus, Holliston, MA, USA).  
The pericardium stripped following a thoracotomy to allow for ligation of the left anterior 
descending coronary artery (LAD).  A 06 prolene ligature was used to occlude blood 
flow for 20 minutes, after which the ligature was released and the myocardium was 
allowed to reperfuse for 2 hours.  The myocardium not subjected to IR injury was 
determined by infusion of (1%) Evans Blue dye into the aortic arch after which the heart 
was excised and cut into 1 mm transverse sections.  Staining of the sections with 2,3,5-
triphenyltetrazolium chloride delineated the area at risk from the infarcted tissue.  The 
area of infarct, expressed as % of area at risk (AAR) was determined Computer 
Planimetry analysis. 
 
qPCR  
Reverse transcription of total lung RNA was performed using a QuantiTect 
reverse transcription kit (Qiagen).  QuantiTect primer assays and SYBR green master 
mix were utilized for Quantitative real-time PCR to examine mRNA expression levels of 
IL-33, OPN and IL-6.  Cycle threshold (Ct) values and internal reference cDNA levels for 
the target genes were determined by an Applied Biosystems StepOnePlus Real-Time 
PCR System (ABI). The cDNA levels were then normalized to GAPDH, used as an 
internal reference, by the equation 2-[ΔCt], where ΔCt is defined as Cttarget- Ctinternal reference.  
Values are reported for an average of 4 independent experiments. 
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ELISA Assays  
IL-33 and sST2 levels were measured in BALF using DuoSet ELISA kits (R&D 
Systems, Minneapolis, MN) in accordance with the manufacturer’s instructions.  Values 
are reported as pg/mL. 
 
Statistical Analyses 
All data were analyzed by one-way ANOVA, with differences between groups 
assessed using Bonferroni post hoc tests or t-tests and are presented as means ± SEM, 
where statistically significant differences were identified with p < 0.05. All statistical 
analysis and graphs were generated using GraphPad Prism 5 software (GraphPad, San 
Diego, CA).  
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RESULTS AND DISCUSSION 
Mast Cells and the IL-33/ST2 Axis Direct MWCNT Induced Lung Fibrosis 
The extent and means by which MWCNTs are able to impact pulmonary toxicity was 
tested by oropharyngeal aspiration of vehicle or MWCNTs (4 mg/kg) in C57BL/6 mice, 
KitW-sh mice, KitW-sh mice reconstituted with BMMCs, KitW-sh mice reconstituted with ST2-/- 
BMMCs and ST2-/- mice.  The dose used to elucidate mechanisms of MWCNT toxicity 
was based upon dose response studies published earlier (Wang et al., 2011a).  In 
addition, the characteristics of the MWCNTs used in this study have been previously 
described (Wang et al., 2011a) and are further detailed in Tables 3.1 & 3.2 and Figure 
3.1.   As indicated in Table 3.2, the MWCNTs were characterized in suspension (10% 
Infasurf® pulmonary surfactant in saline), which also serves as our vehicle control, and 
best exemplifies non-agglomerated MWCNTs in a dispersal medium suited for animal 
studies.  Suspension of MWCNTs in surfactants has been shown to increase dispersal 
and allow for greater stability of the particles, inhibiting aggregate formation and 
producing greater toxicity (Wang et al., 2011b).  A high zeta potential, as displayed in 
Table 3.2, is indicative of a stable suspension, which results in well-dispersed MWCNT. 
In distinguishing the specific underlying mechanism(s) of MWCNT induced 
pulmonary toxicities, we first examined the expression levels of IL-33 in lung tissue.  At 
30 days post-exposure, all groups of mice exposed to MWCNTs demonstrated a 
significant increase in IL-33 mRNA levels in lung tissue homogenate compared to 
vehicle controls (Figure 3.2a).  Protein levels of IL-33 were also significantly elevated in 
bronchoalveolar lavage fluid (BALF) of C57BL/6 mice 30 days following MWCNT 
instillation (Figure 3.2b).  Similarly, IL-33 staining of lung tissue sections from MWCNT 
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exposed C57BL/6 mice was notably increased and not co-localized to the nucleus 
(Figure 3.2c). Contradictory reports regarding IL-33 function have led to more recent 
perspectives of IL-33 as a dual-function cytokine; acting as a traditional cytokine and as 
an intra-nuclear cytokine to regulate gene expression (Haraldsen et al., 2009).  The 
extracellular release of IL-33 has also been debated; however, more recent studies 
demonstrate IL-33 is released by cells following injury and necrosis, unlike apoptotic 
cells that retain IL-33 intracellularly (Luthi et al., 2009).  Induction of both cellular 
apoptosis and necrosis can occur with exposure to MWCNTs in cell types such as 
macrophages and lung epithelial cells (Cavallo et al., 2012; Di Giorgio et al., 2011).  In 
addition, it has been established that there is an increase in IL-33 expression in lung 
epithelial cells during inflammation (Pichery et al., 2012; Talabot-Ayer et al., 2012).  
Therefore, it is possible that our data, displaying increased levels of IL-33 released from 
lung epithelial cells into the BALF and subsequent mast cell activation, are a result of 
cytotoxicity due to MWCNT exposure. 
Additionally, we conducted in vitro studies to confirm the activation of mast cells 
by IL-33 found within the BALF.  It has been reported that IL-33 activation of mast cells 
occurs independent of the FcεRI pathway (Ho et al., 2007).  In our study, BMMCs that 
were treated in culture with BALF collected from C57BL/6 mice instilled with MWCNT 
display significant elevation in IL-6 and osteopontin (OPN) mRNA expression compared 
to BALF from vehicle exposed mice (Figure 3.3).  Increased expression of these two 
genes was not observed when ST2-/- BMMCs were exposed to BALF from MWCNT 
instilled mice (Figure 3.3).  These findings validate that the increase in IL-33 found in 
the lungs of mice treated with MWCNTs is capable of inducing mast cell activation 
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through the ST2 receptor and that IL-33 appears to be the major soluble factor in the 
BALF capable of mast cell activation.   
To further elucidate an IL-33/ST2 axis mechanism in pulmonary inflammation, 
differential cell counts were obtained from BALF following MWCNT instillation.  IL-33 
has been identified as a major determinant in the inflammatory processes of the lung 
(Yagami et al., 2010).  In fact, over expression of IL-33 in transgenic mice demonstrated 
increased levels of cleaved, mature IL-33, resulting in spontaneous pulmonary 
inflammation consisting of increased pro-inflammatory cytokines such as IL-5, IL-8 and 
IL-13, as well as inflammatory cell infiltrates, including neutrophils, in BALF (Zhiguang et 
al., 2010).  In our study, differential cell counts at 1 day post-exposure also 
demonstrated a significantly increased inflammatory cell profile, which is sustained out 
to 30 days following MWCNT instillation (Table 3.3).  At 30 days post-exposure to 
MWCNTs, C57BL/6 mice and KitW-sh mast cell deficient mice reconstituted with BMMCs 
displayed pulmonary inflammation with statistically significant neutrophil recruitment 
(Figure 3.4a).  The infiltration of neutrophils into the lung was absent in KitW-sh, ST2-/-, 
and KitW-sh mice reconstituted with ST2-/- BMMCs (Figure 3.4a).  These data therefore 
suggest the involvement of mast cells, or potentially mast cell derived mediators, in the 
recruitment of neutrophils.  In addition, these data also indicate a role for IL-33 and the 
ST2 receptor in mediating these responses, as inflammation and neutrophil infiltration is 
not observed in the absence of ST2 receptors (Figure 3.4a).  Neutrophils have been 
shown to regulate IL-33 activity through the cleavage of IL-33 into its mature form by 
neutrophil elastase and Cathepsin G (Lefrancais et al., 2012).  Neutrophil proteinase 3 
(PR3) is also proposed to regulate activity of IL-33 by cleavage into its mature form 
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(Bae et al., 2012).  While full length IL-33 is biologically active, it has been reported that 
the activity of mature IL-33 is significantly higher.  Furthermore, both the full length and 
mature forms of IL-33 were detected during neutrophilic infiltration in a murine model of 
acute lung injury (Lefrancais et al., 2012).  It is possible that mast cell recruitment of 
neutrophils along with the capacity of neutrophils in regulating IL-33 activity may impact 
the inflammatory response induced by MWCNTs.  Our data demonstrate a clear role for 
ST2 receptor mediated mast cell activation in MWCNT induced pulmonary 
inflammation; however, additional studies may be required to address the potential 
neutrophil-enhanced IL-33 activity in contributing to these inflammatory responses. 
While previous studies have identified pulmonary fibrotic responses induced by 
MWCNTs, few have examined the underlying mechanisms (Aiso et al., 2010; He et al., 
2011; Mercer et al., 2011; Wang et al., 2011a).  Studies investigating pro-fibrotic 
mechanisms, however, have recognized IL-33 as a component in fibrotic responses 
within the skin, liver and lung (Marvie et al., 2010; Rankin et al., 2010; Yanaba et al., 
2011).  Furthermore, it has been reported that mast cells can also mediate fibrotic 
responses, specifically in response to particulate toxicity as observed with silicosis 
(Brown et al., 2007).  Here, we investigated IL-33 in conjunction with its activation of 
mast cells as an underlying mechanism in MWCNT-specific pulmonary fibrosis.  
Histopathological changes and collagen deposition, along with quantification of collagen 
content were examined at 30 days following MWCNT exposure to assess pulmonary 
fibrotic responses.  C57BL/6 mice and KitW-sh mice reconstituted with BMMCs exhibited 
a robust increase in collagen content with MWCNT instillation, while KitW-sh, ST2-/-, and 
KitW-sh mice reconstituted with ST2-/- BMMCs showed a minimal change in collagen 
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content compared to controls (Figure 3.4b).  These data were further substantiated by 
significantly altered lung histopathology that displayed a wide distribution of collagen 
deposition and granuloma formation throughout the tissue in C57BL/6 and KitW-sh mice 
reconstituted with BMMCs following MWCNT aspiration (Figure 3.4c).  As indicated by 
Masson’s Trichrome staining, fibrotic tissue was identified within granulomas, along with 
the deposition of MWCNTs as depicted by arrows (Figure 3.4c).  MWCNT deposition 
within lung sections was confirmed by Raman spectroscopy (Figure 3.5).  In contrast, 
lung sections from MWCNT instilled KitW-sh mice did not display any collagen deposition 
and minimal granulomatous tissue (Figure 3.4c). ST2-/- and KitW-sh mice reconstituted 
with ST2-/- BMMCs also had an attenuated fibrotic response, suggesting a role for mast 
cells -- or more specifically -- the ST2 receptor in MWCNT induced pulmonary toxicity.   
 
MWCNTs Elicit Changes in Pulmonary Function Dependent Upon Mast Cells and 
IL-33 
We have shown that instillation of MWCNTs impairs pulmonary function in 
C57BL/6 mice due to development of lung inflammation and fibrosis (Wang et al., 
2011a).  To investigate whether mast cells and the IL-33/ST2 axis participate in the 
observed decline in lung function induced by MWCNT exposure, we used the invasive 
forced oscillation technique to measure elastance (E), compliance (C) and Newtonian 
resistance (Rn) in C57BL/6 mice, Kitw-sh mice, Kitw-sh mice reconstituted with BMMC, 
Kitw-sh mice reconstituted with ST2-/- BMMC and ST2-/- mice, 30 days following MWCNT 
exposure.  As previously reported, (Wang et al., 2011a) C57BL/6 mice exhibited a 
significant increase in E, suggesting increased elastic rigidity of the lungs (Figure 3.6a).  
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Similarly, Kitw-sh mice reconstituted with BMMCs exhibited significantly increased E 
following MWCNT exposure, while little or no change in E occurred in Kitw-sh mice, Kitw-sh 
mice reconstituted with ST2-/- BMMC or ST2-/- mice following MWCNT instillation (Figure 
3.6a).  A similar role for mast cells and the IL-33/ST2 pathway was observed when we 
measured C, which reflects the elasticity of the lung parenchyma and is also influenced 
by surface tension, smooth muscle contraction and peripheral airway homogeneity.  
When compared to vehicle treated mice, a reduction in C was observed only in MWCNT 
instilled C57BL/6 and Kitw-sh mice reconstituted with BMMC (Figure 3.6b).  A decrease 
in C was not observed when Kitw-sh mice were reconstituted with ST2-/- BMMC or when 
ST2-/- mice were instilled with MWCNTs. The increased E and the decreased C in 
C57BL/6 mice and Kitw-sh mice reconstituted with BMMC reveal the increased stiffness 
in the fibrotic lung due to MWCNT exposure, which is consistent with findings in other 
models of pulmonary fibrosis (Phillips et al., 2011). These results indicate that the 
decline in pulmonary function as a physiological endpoint induced by MWCNT 
instillation is largely dependent on the presence of mast cells.  In addition, our data 
suggest that the critical mast cell-dependent effects of MWCNT induced pulmonary 
fibrosis require the ability of mast cells to respond to IL-33 via the ST2 receptor.  
A significant increase in Rn following MWCNT exposure was observed in 
C57BL/6 and Kitw-sh mice reconstituted with BMMC, with little to no change in Rn in Kitw-
sh mice, Kitw-sh mice reconstituted with ST2-/- BMMC or ST2-/- mice (Figure 3.6c).  The 
increased Rn suggests that narrowing of the conducting airways is occurring due to 
MWCNT exposure.  While normal Rn values for mice are around 4.2 cmH2O.s/ml, the 
Kitw-sh mice in our study displayed abnormally lower values of Rn compared to other 
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groups (Bates, 2009).  However, the lower Rn observed in the Kitw-sh strain was restored 
to normal values when Kitw-sh mice were reconstituted with C57BL/6 BMMC or ST2-/- 
BMMC.  Studies have shown that Kitw-sh mice reconstituted with BMMCs resulted in 
notably increased numbers of mast cells in the lung, especially along the central 
airways, which is similar to the mast cell distribution found in C57BL/6 mice (Cyphert et 
al., 2011b).  This suggests that mast cells, which are located along the main bronchi, 
have a significant impact on Rn.  These findings identify an important role for IL-33, and 
its receptor ST2, in mast cell mediated changes of Rn.  Our observations of increases in 
E and Rn and a decrease in C in C57BL/6 and Kitw-sh mice reconstituted with BMMC but 
not in Kitw-sh mice, Kitw-sh mice reconstituted with ST2-/- BMMC or ST2-/- mice support the 
critical role of mast cell activation via IL-33/ST2 axis in MWCNT mediated impairment of 
pulmonary function. 
 
MWCNTs Exacerbate Myocardial Ischemia Reperfusion Injury through Mast Cell 
Activation 
Inhalation of ultra-fine, and possibly nano-sized, airborne particulates are well 
known to elicit adverse cardiovascular events mediated through multiple mechanisms 
that are largely unclear.  We have shown that inhalation of particulates such as cerium 
oxide nanoparticles can activate mast cells, promoting the release of Th2 pro-
inflammatory cytokines and resulting in altered vascular reactivity and exacerbation of 
an episode of myocardial ischemia/reperfusion injury in C57BL/6 mice, but not KitW-sh 
mice (Wingard et al., 2011).   Additional studies have established that mast cells and/or 
mast cell products such as chymase are crucial factors in the regulation of 
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cardiovascular responses to tissue injury resulting in inflammation, fibrosis, ventricular 
arrhythmias and myocardial infarction (Nistri et al., 2008; Oyamada et al., 2011).  
We propose that mast cells are able to contribute to cardiovascular dysfunction, 
particularly myocardial IR injury, in part, through activation of the ST2 receptor.  Clinical 
observations have reported increased levels of serum soluble ST2 receptor (sST2) 
associated with decreased left ventricular function and adverse cardiovascular 
outcomes in patients following acute myocardial infarction (Weir et al., 2010).  It was 
therefore of interest to examine how the IL-33/ST2 axis in promoting mast cell activation 
may potentiate cardiovascular toxicities associated with MWCNT exposure.  Work in our 
laboratory has demonstrated that MWCNT instillation in C57BL/6 mice results in 
exacerbation of IR injury in a dose dependent manner at 1 day post-exposure, which 
resolves by 30 days post-exposure (Urankar, In Submission 2012b).  As this 
cardiovascular response has been shown to occur at an earlier time point, we 
investigated the role of mast cells and the IL-33/ST2 axis in IR injury responses in mice 
1 day following exposure to MWCNTs.  Here, we show that instillation of MWCNTs in 
C57BL/6 mice and KitW-sh mice reconstituted with BMMCs exhibit a significant increase 
in myocardial infarct size following ischemia reperfusion compared to vehicle controls 
(Figure 3.7).  An exacerbation of the infarct size by MWCNTs was not observed in KitW-
sh mice or KitW-sh mice reconstituted with ST2-/- BMMCs (Figure 3.7).  Interestingly, ST2-/- 
mice demonstrated a significant exacerbation of infarct size with MWCNT exposure 
compared to vehicle controls, however, the augmented response was not as robust as 
seen in C57BL/6 or KitW-sh mice reconstituted with BMMCs.  These data, while 
consistent with the pulmonary data in substantiating an underlying mast cell specific 
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mechanism associated with MWCNT toxicity, also suggest that the IL-33/ST2 axis may 
not solely contribute to mast cell activation which appears to be the major contributing 
factor in mediating myocardial IR injury responses following MWCNT exposure.   
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Table 3.1 MWCNT Characteristics 
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MWCNT Characteristics 
 
Mean 
Diameter by 
TEM (nm) 
Length 
Range by 
TEM (µm) 
Metal Ash 
Content by 
TGA (% 
weight) 
Spectral 
Content 
(Atomic %) 
Surface 
area  
by BET 
(m2/g) 
Pore 
volume  
by BJH 
(cm3/g) C Fe 
MWCNT 22.5 ± 1.3 10 - 100 4.80 99.6 0.04 113.10 0.69 
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Table 3.2 MWCNT Suspension Characteristics  
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MWCNT Suspension Characteristics 
 
Zeta Potential IEP 
Hydrodynamic Size 
Major peak Minor peak 
MWCNT - 44.6 mV pH = 3.5 180 ± 50 nm 1100 ± 200 nm 
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Figure 3.1Transmission electron microscopy (TEM) of MWCNTs 
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Figure 3.2 IL-33 Gene and Protein Expression in Lungs of Mice 30 Days Post-
Exposure to MWCNT 
 
a, Gene expression of IL-33 in lung tissue, determined by real-time PCR analysis, 
displayed a >2 fold increase in all groups 30 days post-exposure to MWCNT compared 
to vehicle controls.  b, c, Corresponding protein analysis with ELISA (b) and 
immunofluorescence images taken at a magnification of 20x (c).  Values are expressed 
as mean ± SEM (n=6-11). *p < 0.05 compared to strain matched vehicle control. 
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Figure 3.3 BALF from MWCNT Exposed Mice Results in Mast Cell Activation via 
the IL-33/ST2 Axis   
 
Gene expression of IL-6 and osteopontin (OPN), determined by real-time PCR analysis, 
in bone marrow derived mast cells (BMMCs) and ST2-/- BMMCs after exposure to 
bronchoalveolar lavage fluid (BALF) obtained from C57BL/6 1 day following MWCNT 
instillation. Values are expressed as mean ± SEM (n=3-6).  
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Table 3.3 Pulmonary cell populations in mice at 30 days following MWCNT 
exposure 
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Figure 3.4 Neutrophil Cell Counts, Histopathology and Collagen Content in Lungs 
of Mice Instilled with MWCNT 
 
a, Neutrophil cell counts in mice 30 days following instillation with vehicle or MWCNTs.  
b,  Percent collagen change in lung tissue of mice exposed to MWCNT at 30 days 
compared to vehicle control.  c, Masson’s trichrome staining at 30 days post-exposure 
to MWCNT.  As indicated by the bluish color stain, extensive collagen rich granulomas 
and fibrotic tissue were identified in C57BL/6 and KitW-sh mice reconstituted with 
BMMCs.  KitW-sh mice did not display any fibrotic responses, while KitW-sh mice 
reconstituted with ST2-/- BMMCs and ST2-/- mice demonstrated minimal granuloma 
formation, unlike the robust response displayed by mast cell sufficient mice.  
Agglomerates of MWCNT were identified by Raman spectroscopy (Wang et al., 2011a) 
and can be seen within granulomas as indicated by arrows.  Images are representative 
of 6-11 mice per group 30 days post-exposure to MWCNT with original magnifications 
of 20x. All values are expressed as mean ± SEM. *p < 0.05 compared to strain matched 
vehicle control and *p < 0.01 compared to strain matched vehicle control. 
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Figure 3.5 Raman Spectroscopy of Lung Histology 
   
a) A representative microscope image for the unstained lung sections shown in Fig. 3c.  
b) The Raman map for the boxed area shown in a).  Mapping measurement were 
performed using a 514.5 nm Ar+ ion laser coupled to a Dilor XY Raman spectrometer.  
The red color in the map corresponds to the typical spectroscopic signature of 
MWCNTs shown in c).  Green color indicates the absence of peaks shown in c).  c) A 
representative Raman spectrum of MWCNTs, acquired from the sample shown in a), 
exhibits the disorder (or D-band) band at ~1450 cm-1 and the graphitic (or G-band) at 
~1600 cm-1. 
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Figure 3.6 Altered Pulmonary Function Following MWCNT Instillation  
 
 The force oscillatory technique was performed on tracheotomized C57BL/6 mice, Kitw-sh 
mice, Kitw-sh mice reconstituted with BMMC (Kitw-sh + BMMCs), Kitw-sh mice reconstituted 
with ST2-/- BMMCs (Kitw-sh + ST2-/- BMMCs) and ST2-/- mice 30 days post-instillation 
with MWCNTs. The perturbation parameters, E (elastance) (a), C (compliance) (b), and 
Rn (Newtonian resistance) (c) were measured. All values are expressed as mean ± 
SEM (n=5-6).  *p < 0.05 compared to strain matched vehicle control (open bar).  
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Figure 3.7 MWCNT Induced Exacerbation of Myocardial Ischemia Reperfusion 
Injury 
 
Myocardial ischemia reperfusion injury response was assessed as a comparison of 
infarct size to total area at risk (%) in C57BL/6 mice, Kitw-sh mice Kitw-sh mice 
reconstituted with BMMCs (Kitw-sh + BMMCs), Kitw-sh mice reconstituted with ST2-/- 
BMMC (Kitw-sh + ST2-/- BMMCs) and ST2-/- mice, 1 day following exposure to vehicle or 
MWCNT.  All values are expressed as mean ± SEM (n=4-25).  **p < 0.01 compared to 
strain matched vehicle control and ***p < 0.001 compared to strain matched vehicle 
control. 
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CONCLUSION 
In this study, we proposed that MWCNT aspiration actuates the extracellular release 
of IL-33 in lung tissue, leading to the activation of mast cells through the ST2 receptor, 
resulting in an increase in pulmonary inflammation, granuloma and fibrotic tissue 
formation, altered pulmonary function and exacerbated IR injury responses in the heart 
(Figure 3.8).  We have demonstrated that these MWCNT induced toxicities are 
mediated by mast cell activation in both the pulmonary and cardiovascular systems, 
entirely or in part, through the IL-33/ST2 axis.  Furthermore, in identifying the 
mechanism of toxicity, our study provides a crucial insight in delineating efforts to limit 
exposure to nanoparticles and discerning appropriate means of treatment that could be 
needed following exposures.  There are several routes of exposure to MWCNT.  In this 
study we have examined the toxicity of MWCNT through a respiratory exposure, 
however, it is important to acknowledge that there is great potential intravenous 
exposures as MWCNTs are currently display a unique platform for drug delivery.  
Despite the differences in exposure routes, intravenous injection of MWCNTs may 
result in similar toxicities.  Intravenous exposure may distribute MWCNTs into the lung 
tissue to display the mast cell mediated pulmonary toxicities reported in this study.  In 
addition, as mast cells are known to reside in many tissue types, there is still a potential 
for MWCNT to activate mast cells in other areas of the body to produce additional, 
unreported toxicities (Yong, 1997).   
In the current study, we have demonstrated a key role of mast cells as modulators of 
MWCNT toxicity, therefore, targeting mast cells therapeutically may serve to alleviate 
the potential toxicities associated with exposure to MWCNTs, and have also provided a 
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novel screening tool to discern the potential toxicity and concern associated with the 
rising use of nanomaterials.   
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Figure 3.8 Mechanism of MWCNT Induced Pulmonary and Cardiovascular Toxicity 
 
MWCNT induced injury to the lung epithelium results in the release of IL-33.  In the 
lung, IL-33 can activate mast cells through the ST2 receptor to induce pulmonary 
inflammation, granuloma formation and fibrosis, as well as altered lung function.  A 
similar mechanism in the heart may influence the activation of mast cells by IL-33 via 
ST2 receptors to exacerbate ischemia reperfusion injury responses. 
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CHAPTER 4: ADDITIONAL RESULTS 
 
C57BL/6 Mice Display Normal Pulmonary Function 30 Days Following Carbon 
Black Exposure 
In order to corroborate our pulmonary function data and to ensure that the results 
were specific to MWCNT exposure and not a generalized response to particulate 
inhalation, we used carbon black as a reference particle.  Although carbon black is not a 
true negative control as it is not entirely inert, it is often considered to be a more inert 
nanoparticle compared to MWCNTs and does not display the profound toxicities 
associated with MWCNTs and other nanomaterials.  Further, while carbon black 
consists of similar elemental composition, it does not display the same important 
physicochemical properties that potentially contribute to MWCNT toxicity such as high 
aspect ratio and surface area.   
Age matched (9-10 weeks) C57BL/6 mice were exposed to vehicle or 4 mg/kg 
carbon black particles (in vehicle or 10% surfactant/saline) via oropharyngeal aspiration 
and utilized for pulmonary function testing 30 days post-exposure.   The total lung 
resistance (R), compliance (C) and elastance (E) parameters, measured by the 
FlexiVent snapshot perturbation, do not exhibit any statistically significant changes 
between vehicle control or treatment groups with one exception (Figure 4.1).  Mice 
exposed to carbon black did display an increase in R (Figure 4.1a).  This may be due to 
a mild inflammatory response observed in carbon black exposed mice.  The BAL 
differential cell counts of carbon black exposed mice did not show significant increases 
in macrophage or eosinophil counts, but demonstrated slightly elevated numbers of 
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neutrophils and total cells, though not as robust a response as seen with mice instilled 
with MWCNTs (Figure 4.3).  These data confirm carbon black as an appropriate 
reference particle which does not induce robust pulmonary inflammation or impaired 
pulmonary function in parameters associated with pulmonary fibrosis (E and C) 30 days 
following exposure.   
Additional pulmonary function parameters, tissue damping or energy dissipation 
(G), tissue elastance or energy conservation (H), hysteresivity (eta or G/H) of the lung 
parenchyma and Area within the PV loop were also measured with a Quickprime-3 or 
PVr-P loop perturbation.  The increases in G and eta were not observed in mice 
exposed to carbon black and values were similar to mice instilled with vehicle control 
(Figure 4.2).  The increase in G, a parameter that accounts for parenchymal distortion, 
was also absent in carbon black instilled mice, suggesting that these mice may not have 
altered lung morphology and therefore may not elicit adverse pulmonary responses that 
translate into physiologically meaningful changes (Figure 4.2a).  As there are no 
significant changes in H, eta, representative of the G to H ratio, or the ratio of energy 
dissipation to energy conservation in the cycle of inhalation and exhalation, is also 
decreased in carbon black instilled mice, displaying a pattern similar to G (Figure 4.2b 
and 4.2c).  Mice exposed to carbon black most likely lack a significant formation of rigid 
fibrotic tissue. With less energy required to inflate the lung, there is less energy 
dissipation into the tissue, decreased tissue elastance and therefore decreased 
hysteresis or eta.  Area of the PV loop, which reflects the energy or pressure required to 
inflate the lung, displayed no significant difference between carbon black instilled mice 
when compared to vehicle control mice, as would be expected for normal lung tissue 
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since there is most likely an absence of fibrotic tissue which is much stiffer than normal 
lung tissue (Figure 4.2d).   
These data indicate that exposure to carbon black does not alter pulmonary 
function 30 days following instillation, and that the pulmonary toxicity and impaired lung 
function associated with MWCNT exposure is specific to this particular nanomaterial.    
 
Low Gene and Protein Expression Levels of IL-33 in in vitro Lung Epithelial and 
Fibroblast Cell Culture Models 
 In order to fully understand the proposed underlying mechanism of MWCNT 
induced pulmonary and cardiovascular toxicity, we attempted to establish an in vitro 
model that would allow us to test the hypothesis using IL-33 specific antibodies, ST2 
receptor antagonists or even examining interactions between cells types implicated in 
MWCNT associated pulmonary toxicity. 
 As mentioned previously, animals exposed in vivo to MWCNT exhibited 
significant amounts of IL-33 protein in BALF and lung tissue as well as IL-33 expression 
throughout the lung parenchyma and alveolar epithelial cells as indicated by 
immunofluorescence.  In vitro, we first examined mast cells, but were unable detect IL-
33 expression in BMMCs or bone marrow derived macrophages (BMDMs) with 
exposure to MWCNTs (data not shown).  Based on our in vivo data, we also examined 
several pulmonary epithelial cell lines including a transformed murine lung epithelial 
(MLE-12) cell line and the C10 lung epithelial cell line.  Cell lines were grown in either 
supplemented RPMI 1640 or DMEM medium with 5% FBS at 37°C and 5% CO2 until 
70% confluence was reached.  Cells were then treated and collected to assess a variety 
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of endpoints.  As shown in figure 4.4, MWCNTs failed to induce IL-33 gene expression 
in MLE-12 cells at 2, 4 or 24 hours post-exposure (Figure 4.4).  C10 lung epithelial cells 
also demonstrated a lack of IL-33 induction at similar time points of 2, 4, or 8 hours 
following treatment with several different MWCNT doses (Figure 4.5).  Interestingly, a 
high dose 100 ng/mL of LPS was unable to effectively elicit a significant response from 
either MLE-12 or C10 lung epithelial cells.  As such, C10 cells were primed and 
stimulated with a low dose of LPS (20 ng/mL), known to enhance responses and 
activation of numerous cell types, 30 minutes prior to MWCNT exposure.  However, 
neither group of cells, primed or unprimed, demonstrated IL-33 mRNA induction at any 
dose of MWCNT (4.6).  We also investigated the possibility that IL-33 was an 
intracellular cytokine in healthy tissues, which may not be released in the absence of 
tissue damage or necrosis (Haraldsen et al., 2009; Luthi et al., 2009).  We examined 
protein levels of IL-33 in C10 cell culture supernatant collected following 24 hours of 
treatment with 0.1, 1, 10 µg/cm2 MWCNT or 100 ng/mL LPS, but were still unable to 
discern a significant increase in IL-33 protein following exposure to MWCNTs (Figure 
4.7).  Concurrent data were obtained when C10 cell lysate from the same experiment 
was analyzed for IL-33 protein by ELISA (Figure 4.7). C10 cells were also co-cultured 
with BMMCs, both in contact and transwell systems, prior to MWCNT exposure to 
determine if direct contact or proximity to different cell types impacted activation or IL-33 
release.  Co-cultures with BMMCs and C10 cells were not successful in exacting BMMC 
activation reflected through IL-6 expression or C10 expression of IL-33, following 
MWCNT treatment (data not shown).  Several additional lung epithelial cell lines, 
including human A549 (ATTC, Manassas, VA) cells and human primary small airway 
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epithelial cells (SAEC, ATTC, Manassas, VA), were also explored for use as potential in 
vitro models, but yielded analogous outcomes (data not shown). 
Alternatively, a primary murine lung fibroblast (MLF) cell, was also investigated 
as fibroblasts drive the adverse pulmonary fibrotic responses induced by MWCNTs, and 
may contribute to IL-33 production.  However, MLF cells were not responsive to 100 
ng/mL LPS or to different doses of MWCNT treatment and did not enhance IL-33 mRNA 
or protein expression (Figures 4.8 and 4.9). 
Despite an array of negative data in establishing a relevant cell culture model, we 
were able to utilize in vivo models, specifically murine receptor knock out and mast cell 
reconstitution models for the ST2 receptor to address the validity of our proposed 
mechanism, ST2 receptor activation of mast cells by IL-33 in mediating MWCNT 
toxicity.  Our negative data emphasizes the complexity of an organ system response 
and its associated cellular interactions.  In vitro studies are limited by several factors as 
they lack certain microenvironments that may be essential in modulating cell function, 
activation or even phenotype.  While this study has validated an IL-33 and mast cell 
specific mechanism of MWCNT induced toxicity, it is important to acknowledge that 
several presently unknown factors may modulate mast cells and mast cell phenotypes 
to produce a unique response following activation.  
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Figure 4.1 Changes in Pulmonary Function as Determined by Snapshot 
Perturbation After Carbon Black Instillation 
 
The snapshot perturbation was performed in tracheotomized C57BL/6 mice instilled with 
vehicle (10% surfactant in saline) or 4 mg/kg carbon black.  (a), total lung resistance 
(R), (b), compliance (C), and (c), elastance (E) parameters, indicative of whole lung 
respiratory mechanics, were measured.  The mean ± SEM of 4-16 mice per group are 
shown. *p < 0.05 compared with vehicle control mice. 
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Figure 4.2 Changes in Pulmonary Function as Determined by Quicktime-3 and 
PVr-P Perturbation Following Carbon Black Instillation 
 
Quick-prime 3 and PVr-P perturbations were imposed on C57BL/6 mice 30 days 
following exposure to vehicle or 4 mg/kg carbon black.   Quick-prime 3 parameters can 
differentiate specific lung compartments, enabling measurements of (a), tissue damping 
(G), (b) tissue elastance (H) and (c), hysteresivity or eta. From PV loops, the Area (d) 
perturbation parameter was determined. The mean ± SEM of 4-16 mice per group are 
shown and differences between vehicle and treatment groups were not significant 
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Figure 4.3 Differential Cell Counts in C57BL/6 mice 30 Days Following Carbon 
Black Exposure 
 
C57BL/6 mice were exposed to vehicle or 4 mg/kg carbon black and underwent 
bronchoalveolar lavage 30 days following exposure.  Differential cell counts for 
macrophages, neutrophils and eosinophils, along with total cell counts, were obtained 
from cytospins of bronchoalveolar lavage fluid.   The mean ± SEM of 4-9 mice per group 
are shown. *p < 0.05 compared with vehicle control mice.   
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Figure 4.4 Expression of IL-33 mRNA in MLE-12 Murine Lung Epithelial Cells at 2, 
4, and 24 Hours Following MWCNT Exposure  
 
MLE-12, a transformed murine lung epithelial cell line (ATCC, Manassas, VA) was 
cultured in FBS supplemented DMEM medium until 70% confluence was reached.  
Cells were then exposed to vehicle, 0.1, 1 or 10 µg/cm2 MWCNT, 63 µg/cm2 silica, or 
100 ng/mL LPS.  Samples were collected 2 (a), 4 (b) and 24 (c) hours after exposure 
for real-time PCR analysis to determine IL-33 mRNA expression.  All values are 
expressed as fold changes compared to vehicle control.  (n=3) 
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Figure 4.5 Expression of IL-33 mRNA in C10 Lung Epithelial Cells at 2, 4, and 8 
Hours Post-Exposure to MWCNTs  
 
Real-Time PCR analysis was performed on C10 lung epithelial cells collected from 
culture 2 (left panel), 4 (middle panel) or 8 (right panel) hours following vehicle or 
increasing doses of MWCNT to determine mRNA levels of IL-33, expressed as fold 
changes compared to vehicle control samples.  C10 cells collected at the 2 hour time 
point were treated with vehicle, 0.1, 1, 3, or 10 µg/cm2 MWCNT, while cells collected at 
the 4 and 8 hour time points were exposed to vehicle, 0.1, 1, or 10 µg/cm2 MWCNT and 
an additional treatment group exposed to 100 ng/mL LPS, serving as a positive control. 
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Figure 4.6 IL-33 mRNA Expression at 4 Hours Following MWCNT Treatment in C10 
Cells Primed with LPS    
 
C10 lung epithelial cells, cultured to 70% confluence, were primed 20 ng/mL LPS 30 
minutes prior to treatment.  Primed cells were exposed to 0.1, 1, or 10 µg/cm2 MWCNT 
suspended in culture medium, for 4 hours.  Cells that were not primed with 20 ng/mL 
LPS were simultaneously exposed to the same doses of MWCNT, with three additional 
control groups: untreated cells only, 20 ng/mL LPS and 100 ng/mL LPS.  All samples 
were collected 4 hours later for real-Time PCR analysis to quantify IL-33 mRNA 
expression as fold changes compared to vehicle control samples.   
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Figure 4.7 IL-33 Protein Levels in C10 Lung Epithelial Cells 24 Hours Following 
MWCNT Exposure   
 
 C10 cells, untreated or exposed to vehicle, 0.1, 1, 10 µg/cm2 MWCNTs (in 10% 
surfactant/saline), or 100 ng/mL LPS were obtained 24 hours following exposure.  Cell 
supernatant was removed from culture chamber for an ELISA, IL-33 cytokine protein 
analysis (left panel).  The adherent C10 cells were then lysed using a lysis buffer to 
extract protein from within the cell for an additional IL-33 ELISA (right panel). 
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Figure 4.8 IL-33 mRNA Expression in Murine Lung Fibroblasts Following MWCNT 
Exposure   
 
Primary murine lung fibroblasts (MLFs) were grown in a 6 well plate to 70% confluence 
exposed to 0.1, 1 or 10 µg/cm2 MWCNT or 100 ng/mL LPS as a positive control.  
MWCNTs were suspended directly into culture medium instead of a vehicle.  Cells were 
obtained at 2 (left panel) and 4 (right panel) hour time points for real-time PCR analysis 
to determine gene expression of IL-33 (expressed as fold change compared to control 
cells only group).  
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Figure 4.9 IL-33 Protein Expression in Murine Lung Fibroblasts 24 Hours After 
MWCNT Treatment  
 
Primary MLFs, exposed to 1 or 10 µg/cm2 MWCNTs suspended in culture medium, 
were collected at 24 hours following exposure for ELISA analysis to quantify IL-33 
protein within the cells.   
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CHAPTER 5: GENERAL DISCUSSION 
 
 The present study was undertaken to identify the potential role of mast cells and 
the IL-33/ST2 axis as an underlying mechanism in the pulmonary and cardiovascular 
toxicity induced by MWCNT exposure. 
In Aim 1, we examined the role of mast cells in the pulmonary inflammation and 
fibrosis induced by oropharyngeal aspiration of MWCNTs.  To accurately assess the 
pulmonary toxicity, we investigated a dose response with vehicle, 1, 2, and 4 mg/kg 
MWCNT.  At 30 days following MWCNT instillation, C57BL/6 mice displayed an altered 
inflammatory cell profile with significantly increased neutrophil numbers at all doses 
(Table 2.1), associated with increased collagen deposition (Figure 2.5), granulomas and 
fibrotic tissue development at the high dose (Figure 2.6).  Additional analyses 
supporting the observed altered lung morphology demonstrated upregulation in gene 
expression levels of Mmp13, Ccl3 (also known as MIP-1α) and Ccl11 (eotaxin) in BALF 
of mice instilled with the high dose of MWCNT (Figure 2.9).  MMP13, a matrix 
metalloproteinase (MMP), belongs to a group of proteases that can be further 
categorized into collagenases, gelatinases, stromelysins, and membrane-type MMPs, 
known for ability to degrade extracellular matrix proteins (Selman et al., 2000).  MMP13 
in particular has been implicated as a key player in the development of pulmonary 
fibrosis (Flechsig et al., 2010).  Enhanced expression of CCL3 and CCL11, macrophage 
and eosinophil chemoattractants, was also evident following MWCNT exposure, and 
most likely led to the recruitment of macrophages and eosinophils, contributing to the 
observed granuloma formation (Table 2.1).  Together, the imbalance of the extracellular 
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matrix resulting from increased MMP13 activity, along with CCL3 and CCL11 
chemokine induced immune cell infiltration may play an important role in the 
development of pulmonary fibrosis following MWCNT instillation.   
In contrast, investigation of mast cell deficient KitW-sh mice 30 days following 
MWCNT exposure revealed normal lung collagen content and morphology compared to 
vehicle controls (Figure 3.4).  While MWCNT aggregates were still visible throughout 
the lung parenchyma and peribronchiolar spaces, inflammatory cell infiltrates, 
granulomas and fibrotic tissue were not present in the lung tissue of MWCNT instilled 
KitW-sh mice (Figure 3.4).  Our data confirmed previous reports of MWCNT induced 
pulmonary toxicity and provided crucial insight into the potential for mast cells in 
modulating the observed adverse pulmonary responses (Huizar et al., 2011; Ma-Hock 
et al., 2009; Porter et al., 2010).  In addition, we were interested in the physiological 
ramifications of the severe pulmonary toxicities that were observed.  We conducted 
additional studies to evaluate pulmonary function in C57BL/6 mice exposed to varying 
doses MWCNT (1, 2, or 4 mg/kg). 
The forced oscillation technique (FOT) was used to ascertain values for all 
parameters by imposing small pressure oscillations to record pressure and flow 
following various preprogrammed maneuvers, resulting in detailed measurements of 
pulmonary mechanics (Glaab et al., 2007; Shalaby et al., 2010; Vanoirbeek et al., 
2010).  Analysis of pulmonary function parameters demonstrated a significant increase 
in resistance (R) with high dose instillation of MWCNT compared to vehicle controls 
(Figure 2.7).  The R parameter accounts for both conducting airway resistance and 
resistance in the lung parenchyma, while conducting airway resistance alone is 
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distinguished as the Newtonian resistance (Rn) parameter (Shalaby et al., 2010).  
Additional experiments with MWCNT instilled C57BL/6 mice exhibited an increase in Rn 
compared to vehicle controls (Figure 3.6).  The increases in R and Rn are likely to 
reflect the heightened inflammation due to elevated numbers of neutrophils.  The 
presence of granulomas through the parenchyma and peribronchial regions of the lung 
(Figure 2.6) may also contribute to increases in R as airway obstruction hinders airflow, 
thus generating greater resistance through the tissues and airways.  The formation of 
granulomas and fibrotic tissue can also attribute to the significant increase of tissue 
damping or energy dissipation in the lung (G), reflected by increased hysteresivity (eta).  
Fibrotic tissue originates through the process of wound healing, which becomes 
dysregulated, resulting in the development of thicker, more rigid scar tissue (or fibrotic 
tissue) (Wynn, 2011). The rigidity of fibrotic tissue results in greater energy dissipation, 
G, (or tissue damping) throughout the lung tissue during inhalation; however, it should 
also have enhanced recoil in the release of air, which would be evident in the H or 
tissue elastance parameter.  Although C57BL/6 mice instilled with MWCNT do not 
mirror this increase in H, overall increases in G, as well as eta (ratio of tissue damping 
to tissue elastance, G/H) strongly suggest the impairment of lung function is due to the 
presence of fibrotic tissue (Figures 2.7 and 4.2).   
KitW-sh exposed to 4 mg/kg MWCNTs did not demonstrate any significant 
changes in pulmonary function parameters compared to strain matched vehicle controls 
(Figure 3.6 and data not shown), reinforcing the hypothesis that the presence of mast 
cells as key players in pulmonary inflammation, fibrosis and altered lung function incited 
by MWCNTs. 
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 The focus of aims 2 and 3 was to determine whether IL-33 activation of mast 
cells via the ST2 receptor attributed to the underlying mechanism of MWCNT induced 
toxicity.  While we were not able to fully investigate this aim in vitro, due to insufficient 
cell culture models, we were able to incite mast cell activation and release of IL-6 and 
OPN in BMMCs exposed to BALF taken from MWCNT exposed C57BL/6 mice.  To 
ensure the mast cell activation was IL-33 mediated, we cultured BMMCs from ST2-/- 
mice and exposed them to the same BALF, but were unable to induce IL-6 or OPN 
expression.  In vivo, we were able to thoroughly examine IL-33 activation of mast cells 
through the ST2 receptor.  As mast cell deficient mice did not display pulmonary 
inflammation, fibrosis or impaired lung function, a mast cell reconstitution animal model 
was used.  KitW-sh reconstituted with cultured, mature BMMCs demonstrated results 
similar to C57BL/6 mice.  They exhibited increased pulmonary cell infiltrates, collagen 
deposition, granuloma formation and impaired lung function 30 days following MWCNT 
exposure.  While these data confirmed a role for mast cells in MWCNT induced toxicity, 
they did not address the involvement of the IL-33/ST2 axis in the underlying 
mechanism.  To examine the role of the IL-33/ST2 axis, we utilized a global ST2-/- 
mouse model in conjunction with mast cell deficient mice reconstituted with ST2-/- 
BMMCs cultured from the ST2-/- mouse model.  As with any global knock out model, 
results could not be attributed only to mast cell specific ST2 receptors as several cell 
types, including Th2 cells have been shown to express the receptor (Yagami et al., 
2010).  However, the reconstitution of the KitW-sh with BMMCs from ST2-/- mice was 
able to provide a more direct approach for assessing the deficiency of ST2 on mast 
cells.   
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 Investigation of pulmonary inflammation demonstrated no significant increases in 
inflammatory cell types in KitW-sh, ST2-/- mice and KitW-sh reconstituted with ST2-/- 
BMMCs.  Interestingly, C67BL/6 and KitW-sh reconstituted with wild type BMMCs display 
significant elevations in neutrophils within the lung following MWCNT exposure (Table 
3.3 and Figure 3.4).  This may indicate an important role for neutrophils in IL-33 
modulation of the resulting pulmonary inflammation.  As increased neutrophils were only 
observed in animals possessing mast cells with fully functional ST2 receptors, it is 
possible that activation of mast cells through the ST2 receptor leads to the release of 
inflammatory cytokines which act to recruit neutrophils into the lungs.  Furthermore, 
neutrophils have been shown to regulate the activity of IL-33 through the release of 
neutrophil elastase, cathepsin G and neutrophil PR3, all of which act to cleave IL-33 into 
a more mature form with greater biological activity then full length IL-33 (Bae et al., 
2012; Lefrancais et al., 2012).  This may greatly enhance mast cell activation and 
subsequent cytokine release facilitating greater inflammation similar to a positive 
feedback cycle.  However, the abundant release of myeloperoxidase by neutrophils may 
also act as a compensatory mechanism in response to MWCNTs.  Myeloperoxidase is 
suggested to play a role in the clearance and oxidative degradation of CNTs through an 
H2O2 reaction yielding reactive intermediates that produce hypochlorous acid (HOCl) 
(Shvedova et al., 2012).  Further investigation is required to elucidate the complex 
functions of immune cell mediators to determine the true nature of the neutrophilic 
response in MWCNT-induced pulmonary inflammation. 
As with the pulmonary inflammatory responses, MWCNT induced fibrotic 
outcomes including collagen deposition and granuloma formation were only observed in 
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C57BL/6 and KitW-sh reconstituted with BMMCs.  MWCNT instilled KitW-sh, KitW-sh 
reconstituted with ST2-/- BMMCs, and ST2-/- mice did not exhibit significant increase in 
collagen content (Figure 3.4).  While KitW-sh displayed normal lung morphology, lung 
sections from KitW-sh reconstituted with ST2-/- BMMCs, and ST2-/- mice did show normal 
lung tissue with areas of minimal granulomatous tissue (Figure 3.4).  Altogether, these 
data validate a role for mast cells and the IL-33/ST2 axis in mediating the observed 
pulmonary fibrosis following MWCNT exposure.  As anticipated, the changes in lung 
morphology evident in C57BL/6 and KitW-sh reconstituted with BMMCs exposed to 
MWCNT also translated into physiological changes with significant increases in 
elastance (E) potentially due to the more pronounced recoil or rigidity of fibrotic tissue 
(Figure 3.6).  Classically, fibrotic tissue exhibits increases in E coupled with decreases 
in compliance (C), which reflects elasticity or the resistance of recoil in the lung tissue.  
While C57BL/6 mice did not demonstrate a statistically significant increase in C, a slight 
elevation was seen in MWCNT instilled mice.  However, in KitW-sh reconstituted with 
BMMCs and exposed to MWCNT, the presence of mast cells resulted in increased C 
values compared to strain matched vehicle control mice or mice completely deficient of 
mast cells.  In addition, increases in the Newtonian resistance (Rn), a measure 
accounting for the narrowing of conducting airways, were evident in both the C57BL/6 
and KitW-sh reconstituted with BMMCs, demonstrating the clear involvement of mast 
cells in modulating these pulmonary function parameters (Figure 3.6).  The increase in 
Rn may be due to the fact that mast cells are ideally located in close proximity to 
bronchial epithelial cells of the conducting airways, reported to produce IL-33, thus 
possibly activating mast cells and resulting in subsequent release of mediators that may 
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impact resistance of the conducting airways (Cyphert et al., 2011a; Kurowska-Stolarska 
et al., 2009).  Mice that lacked mast cells or lacked functional ST2 receptors on mast 
cells did not have any impairment in pulmonary function following MWCNT exposure, 
suggesting that mast cell activation through the ST2 receptor is essential in actuating 
MWCNT induced pulmonary inflammation, fibrosis and altered lung function (Figure 
3.6). 
In addition to the proposed aims in this dissertation, the cardiovascular toxicity of 
MWCNTs was also investigated to determine if the proposed underlying mechanism 
involving mast cells and the IL-33/ST2 axis also governed the adverse cardiovascular 
effects associated with MWCNTs.  Several studies have implicated particulate exposure 
such as cerium oxide in adverse cardiovascular events and previous studies from our 
lab and others have established a role for mast cells in modulating the induced changes 
in vascular reactivity and exacerbating myocardial IR injury through the release of Th2 
cytokines (Nistri et al., 2008; Wingard et al., 2011).  Given the complexity of mediators 
that may be released by mast cells, it is important to consider the cardiac mast cell 
phenotype.  Mast cell phenotypes can impact mast cell function through a variety of 
means.  The presence of the MCTC mast cell phenotype in cardiac tissue has been 
reported, but is further supported by a study which implicates mast cell chymase in 
acute myocardial ischemia reperfusion (IR) injury and subsequent increases in 
activation of mediators such as MMP-9, shown to be associated with exacerbation of 
infarct size, and SCF, known to induce mast cell proliferation (Oyamada et al., 2011; 
Sperr et al., 1994).  In a porcine survival model of IR injury response, mast cell numbers 
in the infarct area were significantly increased at 1 and 21 days following IR injury 
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(Kwon et al., 2011). Our data, also examining myocardial IR injury response, exhibit 
significant exacerbation of IR injury in C57BL/6 and mast cell deficient mice 
reconstituted with wild types BMMCs post-exposure to MWCNT, suggesting the 
involvement of mast cells and the IL-33/ST2 axis in modulating the response (Figure 
3.7).  Mast cell deficient mice and mast cell deficient mice reconstituted with ST2 -/- 
BMMCs did not show any exacerbation of the IR injury compared controls after MWCNT 
instillation (Figure 3.7).  Interestingly ST2-/- mice exposed to MWCNT demonstrated a 
slight exacerbation, though significantly attenuated compared to C57BL/6 and mast cell 
deficient mice, suggesting that our proposed mechanism of cardiovascular toxicity 
mediated by mast cells may not be solely dictated by activation through the ST2 
receptor (Figure 3.7).   
In this study, the proposed mechanism of MWCNT induced toxicity was validated 
through the use of the KitW-sh and the KitW-sh reconstitution model wherein cultured mast 
cells were injected back into the mast cell deficient mouse.  The use of KitW-sh mice, 
evolving from a spontaneously occurring inversion mutation in the c-kit transcriptional 
regulatory region of mouse chromosome 5, is a relatively recent occurrence, but is 
largely favored over the use of previous mast cell deficient mouse models for several 
reasons (Wolters et al., 2005).  Unlike the previous WBB6F1-KitW/W-v mouse model, KitW-
sh mice do not display profound phenotypic abnormalities including sterility, macrolytic 
anemia, gastric ulcers, spontaneous dermatitis, and many other conditions 
(Grimbaldeston et al., 2005).  In fact, KitW-sh mice only demonstrate an impairment of 
skin pigmentation, making them appear white in color, but otherwise display normal 
mouse phenotypes with normal levels of lymphoid cells and hematopoietic cells, with 
  
163 
 
the exception of mast cells (Grimbaldeston et al., 2005).  Additionally, this model has 
responded well to adoptive transfer or reconstitution of normal, c-Kit expressing, 
cultured mast whether by intravenous, intradermal or other means of transplantation 
(Grimbaldeston et al., 2005; Wolters et al., 2005).  Indeed, this makes the KitW-sh mouse 
a very attractive model for investigating mast cell function; however, the model does 
display limitations due to the lack of c-kit expression.  The c-Kit receptor is not only 
central in the development of mast cells, it is also important for other hematopoietic and 
immune cell lineages.  While KitW-sh mice demonstrate normal immune cell counts, the 
extent of immune function in various cell types is not fully understood.  Along with mast 
cells, dendritic cells and natural killer cells have been shown to retain expression of the 
c-Kit receptor, suggesting that it may play numerous roles in different facets of the 
immune system.  In dendritic cells, it has been shown that c-Kit and SCF expression is 
upregulated in the presence of Th2 or Th17 inducing stimuli (Ray et al., 2010).  The c-
Kit receptor has also been shown to influence generation of natural killer cells, 
impacting survival, proliferation and lytic function once maturity has been reached (Ray 
et al., 2010).  These mast cell-independent functions of c-Kit in the immune system 
demonstrate the potential for altered and compensatory immune responses in KitW-sh 
mice.  Therefore, the use of KitW-sh mice adds a layer of complexity in delineating the 
effects observed following MWCNT exposure and whether they are due to mast cell 
deficiency or the lack of c-Kit expression.  Though evidence for our proposed mast cell 
mediated mechanism is compelling, it is important to acknowledge the limitations of this 
animal model.   
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Interestingly, a recent study has investigated the interaction of signaling 
mechanisms between the c-kit receptor and the IL-33 receptor.  In both human and 
murine mast cells, cross activation of the IL-33 receptor, ST2, and the c-kit receptor has 
been reported to occur through trimerization of ST2 with IL-1RAcP and c-kit, the latter of 
which are constitutively complexed (Drube et al., 2010). Therefore, the trimerization of 
ST2 results in integrated IL-33 and c-Kit signal transduction pathways, enhanced 
activation of signaling molecules and robust cellular responses (Drube et al., 2010).  In 
the presence of SCF, a ligand for c-Kit, the activation of the ST2 receptor by IL-33 yields 
a synergistic response, which may have yielded weak responses with IL-33 activation 
alone or a complete lack of response in the SCF activation of c-Kit alone (Drube et al., 
2010).  The implications of this study on the current body of work are significant.  It is 
possible that the lack of IL-33 and ST2 mediated pulmonary and cardiovascular toxicity 
induced by MWCNT in KitW-sh mice may be influenced by a lack of integrated ST2 and 
c-Kit signaling to induce the level of response observed in C57BL/6 mice.  At present 
the direct impact of these integrated signaling pathways beyond the cellular level, 
particularly on mast cell function in immune responses and disease pathology, is 
unknown.    
Overall, the data generated from this study has contributed greatly to our 
understanding of the underlying mechanisms of MWCNT toxicity.  Figure 5.1, a detailed 
schematic of our proposed mechanism of MWCNT-toxicity, illustrates how MWCNT 
exposure may damage and incite lung epithelial cells to release IL-33.  IL-33 activation 
of mast cells through the ST2 receptor initiates a cascade of downstream effects 
leading to MWCNT induced pulmonary and cardiovascular toxicity.  Mast cell activation 
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can result in the release of a variety of mediators and engage effector cells in 
contributing to the immune response.  However, many of cytokines released by 
activated mast cells and downstream effector cells following MWCNT still remain to be 
investigated, though other studies have implicated a host of mediators that could 
potentially be released by mast cells and are involved in the pathophysiology of 
conditions similar to those observed with MWCNT pulmonary toxicity.  Several 
cytokines released by mast cells, including TNF-α and IL-8 act to recruit neutrophils to 
the site of inflammation, wherein neutrophils produce additional pro-inflammatory 
cytokines contributing to total lung inflammation (Zhang et al., 1992).  As depicted in 
figure 5.1, neutrophil proteases (elastase, cathepsin G and PR3) may then act on IL-33 
cleaving it to its more active mature form, enhancing mast cell activation (Bae et al., 
2012; Lefrancais et al., 2012).  Additionally, mast cells can act on macrophages through 
the release of IL-4, IL-6, IL-13, MCP-1 and other cytokines, involving recruitment of 
macrophage precursors and activation of macrophages to produce additional Th2 pro-
inflammatory and pro-fibrotic cytokines such as TGF-β (Lee et al., 2001).  Several Th2 
cytokines and growth factors also drive fibroblast activation or proliferation, including 
TGF-β, IL-13, bFGF, and PDGF-AA (Inoue et al., 1996; Ryman-Rasmussen et al., 
2009b).  Many of these mediators, such as TGF-β, have enhanced activation in vivo 
due to release of mast cell proteases, specifically chymase.  The release of chymase, 
typically associated with the MCTC mast cell phenotype, suggests a shift in phenotype in 
pulmonary fibrotic pathologies (Hamada et al., 2000; Lang et al., 2010; Orito et al., 
2004).  It is possible that MWCNT exposure may lead to an induction of mediators like 
TGF-β, known to promote a shift in mast cell phenotype from MCT to MCTC.  The 
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immune response following mast cell activation in lungs exposed to MWCNTs has been 
shown to induce significant pulmonary inflammation and fibrosis, manifesting 
physiologically with impairment of pulmonary function.  In the heart, mast cell activation 
by IL-33 through the ST2 receptor may result in the release of chymase, again, from 
mast cells with the MCTC phenotypes, found abundantly through heart tissue (Oyamada 
et al., 2011).  Further studies need to be conducted to determine the release of specific 
cytokines, which may impact exacerbation of myocardial IR injury responses.  Thus far, 
we have established a role for IL-33 activation of mast cells via the ST2 receptor in 
mediating adverse pulmonary and cardiovascular resulting from MWCNT exposure.  
This novel mechanism may prove to highlight potential mast cell specific therapeutics to 
alleviate toxicity of nanoparticle exposure or adverse effects to nanomedicines.  More 
importantly, distinguishing critical underlying mechanisms of nanomaterial toxicity may 
enable the development of better, more efficient screening tools to address heightened 
concerns regarding the risks of nanoparticle exposure to human health.  
 
 
Future Studies 
Given the minor drawbacks of our animal models, an additional model may be 
used to support the findings of our study.  One model that may potentially transcend the 
shortcomings of KitW-sh mice is the “Cre-mediated mast cell eradication” (Cre-Master) 
mouse model, established through the insertion of a Cre recombinase into the mast cell 
carboxypeptidase A3 gene locus (Feyerabend et al., 2011).  The use of this particular 
Cre-Lox system resulted in a serious deficiency of mast cells with Cre recombinase 
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expression.  As the Cre-Lox recombination system specifically targets carboxypeptidase 
A3, which is largely expressed in mast cells and perhaps only minimally expressed in 
basophils, Cre-Master mice do not display any other abnormalities with the exception of 
slightly decreased basophil numbers (Feyerabend et al., 2011).  Unlike KitW-sh mice, 
Cre-Master mice are not impacted by a lack of c-Kit function in other hematopoietic cell 
types, enabling them to display completely normal immune systems (Feyerabend et al., 
2011).  In the context of this study, the Cre-Master mouse model may prove to further 
delineate the exact role of IL-33/ST2 axis activation of mast cells and their downstream 
responses from the potential c-Kit receptor interactions. Furthermore, Cre-Master mice 
provide another major advantage in that these mice are not limited to the C57BL/6 
genetic background.  Strain controls for KitW-sh mice are generally C57BL/6 mice or mice 
that share a similar genetic background, but as the Cre-Lox system is an inducible 
expression of Cre resulting in mast cell deficiency, no strain controls would be required 
and mice with the other genetic backgrounds could be utilized.  Future studies involving 
the Cre-Master mice would be highly advantageous.   
Several additional studies may be conducted in the future to validate and 
address more specific aspects of this mast cell mediated mechanism of MWCNT 
toxicity.  In order to establish the mast cell as realistic target for therapeutics to treat 
side effects of nanomedicines or hazardous occupational exposures to nanomaterials, it 
is essential to investigate the potential of mast cell specific drugs in alleviating MWCNT 
induced pulmonary and cardiovascular toxicity.  Utilizing our current wild type murine 
model, several mast cell stabilizers, such as cromolyn sodium (Intal ®) or Nedocromil 
(Tilade ®) could be administered following exposure to MWCNTs.  Currently, mast cell 
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stabilizers in an aerosol or inhaler formulation are indicated for the prevention of asthma 
symptoms and other allergic conditions.  To optimize the effectiveness of the drug, a 
dose and time course study would be required in delineating a therapeutic window.  It 
would also be prudent to consider a mast cell stabilizer as a preventative measure of 
MWCNT toxicity, especially in occupational settings where nanomaterials may pose 
greater health hazards as the risks of exposure are constant.  Alternatively, another 
therapeutic possibility would be the use of an IL-33 specific monoclonal antibody to 
inhibit MWCNT toxicity.  Though other monoclonal antibodies like TNF-α, indicated for 
autoimmune diseases, are currently available on the market, no therapeutic IL-33 
antibody has been FDA-approved.  Pre-treatment of animals with a specific IL-33 
antibody prior to MWCNT exposure may attenuate the subsequent pulmonary and 
cardiovascular responses, providing a feasible means of reducing the risks and toxicity 
associated with MWNCTs. 
In our study, we demonstrate that IL-33 activation of mast cells through the ST2 
receptor is crucial in modulating MWCNT induced toxicity through the release of pro-
inflammatory or pro-fibrotic mediators.  While we have established a previously 
unknown mechanism of toxicity, we have yet to explore the effects downstream of mast 
cell activation.  As previously mentioned, mast cells exhibit extraordinary phenotypic 
plasticity, enabling them to effectively actuate differential immune responses in a variety 
of conditions.  Changes in mast cell phenotype have been documented in the pathology 
of conditions such as asthma (Balzar et al., 2011).  To determine how changes in 
phenotypes are implicated in mast cell and IL-33/ST2 axis mediated MWCNT toxicity, 
we would need to characterize mast cell phenotypes within the lung, alterations of 
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phenotypes following MWCNT exposure, and identify the specific mediators released.  
Mast cell phenotypes are also known to be inherently distinct in different tissues types.  
In this study, mast cells and the IL-33/ST2 axis were determined to be important in the 
adverse cardiovascular responses elicited by MWCNTs.  As previously mentioned, the 
majority of cardiac mast cells are reported to maintain a MCTC phenotype and though 
their exact role cardiovascular pathophysiology is currently unknown, chymase, tryptase 
and other mediators of cardiac mast cells, are important factors in a variety of 
pathological conditions (Oyamada et al., 2011; Sperr et al., 1994).  Elucidating the 
complexities of mast cell function regulated by phenotype within the confines of our 
recently established mechanism of MWCNT induced toxicity could greatly add to our 
understanding of mast cell involvement in disease pathologies as well as environmental 
toxicities.   
In this study, we have not yet established whether the MWCNT induced 
cardiovascular toxicities result directly from the IL-33 activation of cardiac mast cells or 
indirectly from the mediators released by IL-33 activation of pulmonary mast cells into 
cardiovascular tissues.  To address this question, an effective technique would be the 
use of the Langendorff perfused isolated heart system.  This type of experiment would 
require an excision of the heart from the animal following MWCNT exposure and 
perfusion in a chamber with physiologically relevant medium.  This system would enable 
us to investigate an endpoint similar to the in vivo IR injury model used in this study.  By 
using a global or regional IR model in the Langendorff heart system, we would be able 
to ascertain if the observed MWCNT-induced cardiovascular toxicity was a direct result 
of IL-33 activation of cardiac mast cells, as pulmonary mast cells would not be present 
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(Skrzypiec-Spring et al., 2007).  These results could be validated through the use of IL-
33 antibodies, ST2 receptor antagonists, cromolyn sodium or nedocromil directly into 
the isolated heart perfusion chamber.  Furthermore, additional cardiovascular studies 
may be conducted with the Langendorff heart system to examine alterations in 
physiological functions resulting from MWCNT exposure, including biochemical analysis 
with the release of cytokines and chemokines from the heart, and electrocardiographs 
to assess abnormal cardiac rhythms.  
Although the main focus of this study has been on a respiratory exposure to 
MWCNTs, the use of MWCNTs in a variety of biomedical applications has assuredly 
increased the potential for other routes of exposures.  As drug delivery and 
nanomedicine remain a key topic of interest in the nanotechnology area, exposure 
through an intravenous route is an important field of study (Baughman et al., 2002; 
Martin and Kohli, 2003).  While some studies have reported the toxicity of intravenous 
MWCNT exposure, few have yet to examine the implications of mast cells in the 
subsequently observed toxicities (Jain et al., 2011; Ji et al., 2009).  Intravenous 
administration will likely distribute MWCNTs to numerous areas of the body.  
Distribution of MWCNTs to the lungs may result in some of the mast cell and IL-33/ST2 
axis driven pulmonary toxicities reported in this study.  However, as mast cells are 
known to reside in numerous tissues types, it is possible for MWCNTs to impact mast 
cell activation and induce toxicities in several areas of the body through the IL-33/ST2 
pathway or additional mechanisms of mast cell activation.  Thus, the route of MWCNT 
exposure may be a key factor in determining the associated mast cell mediated 
toxicities.   
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Future Directions in Nanotoxicology 
 The field of nanotechnology has expanded enormously over the past decade, 
thanks to significant advances in analytical techniques enabling manipulation of 
materials at the nano-scale.  In the creation of CNTs, newer discoveries were made 
highlighting structural configurations that enabled unique thermal, electrical and 
mechanical properties, making them attractive options for numerous applications 
(Bethune, 1993).  The incredible diversity in the properties and subsequent applications 
of nanoparticles places a huge burden on safety regulations.  Currently, the National 
Institute for Occupational Safety and Health (NIOSH) has issued a bulletin on 
occupational exposures to carbon nanotubes, nanofibers and other nanomaterials, 
detailing concentrations levels of nanomaterials suggested to be safer and present 
minimal risks to exposed workers (NIOSH, 2010).  The recommended exposure level 
for CNTs is suggested not to exceed 7 µg/cm3, the lowest detectable value using the 
current analytical method, suggesting even lower exposures may still pose a threat to 
human health (NIOSH, 2010).  While this report has indicated the gravity of 
nanomaterial exposures, no current regulations are in place to govern the means by 
which nanoparticles are used or the threat they pose, not only to human health, but also 
to the environment. 
 Further study of nanomaterial toxicity will provide support for instituting 
regulations and accurately assessing the risks of nanomaterial exposure.  Therein lies a 
great challenge as nanoparticle toxicity is dictated by a multitude of facets and 
characteristics that constitute any single type of nanoparticle.  The distinguishing 
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characteristics of each type of nanomaterial, including chemical composition, shape, 
size, surface area and function groups, may result in distinctly unique toxicities, making 
it difficult to apply generalized means of therapy or risk assessments to all nanomaterial 
exposures (Luo et al., 2012; Zhao and Castranova, 2011).  Establishing appropriate 
therapeutics for nanoparticle exposure is, in and of itself, a formidable task.  Unlike 
other toxicological exposures, the size of nanomaterials enables greater surface areas 
and heightened potential for biological interactions within the body.   
The toxicological studies that have been conducted to assess the toxicity of 
nanomaterials provide data in support of establishing nanoparticle regulation.  These 
studies have yet to effectively set a no observable effect level (NOEL) or the level at 
which a given nanoparticle does not display toxic effects, suggesting any amount 
exposure to a nanoparticle may be detrimental.  Assessing and characterizing the 
hazards of nanoparticles is crucial in understanding the potential risks to human health.  
The margin of exposure, or the ratio of the NOEL to estimated exposure dose, is often 
used as a tool in risk assessments as a means of establishing the toxicity level of a 
given nanomaterial.  The NOEL for CNTs, however, is unknown and the estimated 
human exposure levels remain ambiguous, therefore making it difficult to identify the 
margin of exposure.  This study has reported important mechanistic findings of MWCNT 
toxicity at an exposure dose that is comparable to a high human exposure level.  While 
MWCNT exposure in humans may not necessarily reach such high levels, lower levels 
of exposure may still result in toxicities following inhalation, many of which have been 
detailed in this study.  The doses utilized in this animal study are relevant and 
comparable to potential human exposures and outline toxicological endpoints that may 
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be meaningful in humans.  However, it is clear that there is a need for additional studies 
regarding CNT toxicity, particularly in assessing current exposures and toxicities in 
humans, so that we may better assess the risks these nanomaterials pose.   
Current toxicological means for assessing nanomaterial toxicity are costly and 
time consuming, requiring the use of appropriate animal models and targeted in vitro 
systems to adequately address certain toxicities.  The sheer volume of distinct 
nanomaterials currently produced makes it impractical to utilize traditional toxicological 
means as a screening platform for nanotoxicity.  There is a profound need for better 
toxicity testing tools and the use of high throughput screening may provide an effective 
alternate to animal studies and high yield of data, imparting greater insight to how 
engineered nanoparticle properties are associated with certain toxicity responses 
(Damoiseaux et al., 2011).  While traditional animal studies remain central to 
investigating mechanisms of toxicity, high throughput screening will enable efficient 
identification of known toxicities and toxicological mechanisms, given the high potential 
for many novel nanomaterials to revolutionize biomedical applications and 
nanomedicines.  In this study, the mast cell serves as a crucial cell type in modulating 
MWCNT toxicity, and thus may be an invaluable source of information for the 
development of high throughput screening systems for future studies in nanotoxicology. 
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Figure 5.1 Schematic Representation of an IL-33/ST2 Axis and Mast Cell Mediated 
Mechanism of MWCNT Induced Toxicity  
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